

1
2
3
4 **Title:** EFFECTS OF POSTNATAL GLUCOCORTICOIDS ON BRAIN STRUCTURE IN
5
6
7 PRETERM INFANTS, A SCOPING REVIEW
8
9

10
11 **Authors:** Isabella Robles^a; Margarita Alethea Eidsness^b; Katherine E. Travis^b, PhD;
12
13
14 Heidi M Feldman^b, MD, PhD; Sarah E. Dubner^{b*}, MD
15
16
17
18

19 ^aUniversity of California Davis, School of Medicine; ^bDivision of Developmental-
20
21 Behavioral Pediatrics, Department of Pediatrics, Stanford University School of Medicine
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 * Corresponding Author:
53 Sarah E. Dubner, MD
54 Developmental-Behavioral Pediatrics
55 Stanford University School of Medicine
56 3145 Porter Drive
57 MC 5395
58 Palo Alto, CA 94304
59 s dubner@stanford.edu
60
61
62
63
64
65

HIGHLIGHTS

- Few studies examine postnatal glucocorticoid effects on preterm human brain structure
- Dexamethasone use in preterm infants is associated reduced overall brain volumes
- Dexamethasone use in preterm infants is associated with reduced cerebellar volumes
- Hydrocortisone use in preterm infants is not consistently correlated with adverse brain effects
- Studies of glucocorticoid use in preterm infants should assess brain structures

1
2
3
4 **ABSTRACT**

5
6 Glucocorticoids (GC) are used in neonatal intensive care units to prevent or reduce the
7 severity of chronic lung disease in preterm infants and have been implicated in impaired
8 neurodevelopment. Our objective was to identify what is known about the effects of
9 postnatal GC treatment in human preterm infants on structural brain development and
10 to identify gaps in the literature. Following Arksey and O'Malley's scoping review
11 methodological framework, we searched scientific literature databases for original
12 research on human preterm infants, postnatal GCs, and brain structure. 11 studies
13 assessed the effects of GCs on structural brain outcomes. 56 studies reported brain
14 injury, but not structure. Dexamethasone was consistently associated with decreased
15 total and regional brain volumes, including cerebellar volumes. Hydrocortisone was
16 often, but not always associated with absence of brain volume differences. No studies
17 examined the impact of inhaled GC on brain structure. Additional research on the
18 effects of neonatal GCs after preterm birth on a variety of structural brain measures is
19 required for understanding contributions to neurodevelopment and informing practice
20 guidelines.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **KEYWORDS:** glucocorticoids, prematurity, brain, imaging, human
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1.0 INTRODUCTION

Glucocorticoids (GC) are a class of steroid hormones that may be produced endogenously by the adrenal gland or provided exogenously as an anti-inflammatory or immunosuppressant medication. Exogenous GC are highly effective as anti-inflammatory medications, but are associated with multiple complications, especially after prolonged use. Exogenous GC are graded in terms of potency; dexamethasone is a potent GC whereas hydrocortisone is a less potent GC. Infants born preterm (PT), particularly those born more than 2 months before their due date, labelled very and extremely preterm, often require support for basic bodily functions, such as mechanical ventilation for respiratory illness. These PT children are at high risk for multiple inflammatory complications during their neonatal hospitalization, including a severe inflammatory chronic lung disease, called bronchopulmonary dysplasia (BPD). They are also at risk for long-term neurodevelopmental disorders, particularly among those children with inflammatory conditions, such as BPD (Gallini et al., 2021; Patra et al., 2017). The use of exogenous GC for infants born preterm (PT) in the neonatal intensive care unit has been a controversial topic, much debated in recent decades. GCs are commonly administered to PT infants to reduce the incidence and severity of BPD, which, in turn, is a major risk factor for mortality and neurodevelopmental disability in children born PT. The overall aim of this scoping review is to review the existing literature in human infants to determine what is known about the impact of exogenous GC, administered in the neonatal intensive care unit to prevent or reduce the severity of BPD, in relation to early brain structural development.

1
2
3
4 Despite widespread use, multiple investigations have questioned whether
5
6 administration of GC is appropriate for preterm infants for several important reasons: (1)
7
8 studies have failed to show a clear and consistent benefit of the medication in
9
10 decreasing rates or severity of BPD (Cummings et al., 2022), (2) some studies have
11
12 shown poor neurodevelopmental outcomes in GC-treated preterm infants, especially
13
14 after administration of dexamethasone (Cummings et al., 2022), and (3) animal studies
15
16 have found adverse effect of GCs on brain structures (Huang et al., 1999). It is
17
18 generally assumed that brain structural metrics are associated both with neonatal
19
20 clinical experience (Volpe, 2009) and with neurodevelopmental outcomes (Ment et al.,
21
22 2009). Thus, we embarked on this review. We anticipated variation in the types of GCs
23
24 used and in the methods of neuroimaging used to evaluate brain structure, both limiting
25
26 our ability to conduct a systematic review and meta-analysis. We therefore
27
28 conceptualized this review as a scoping review to synthesize what is currently known in
29
30 the field, identify gaps in the literature, and direct future research questions.
31
32
33
34
35
36
37

38 **1.1 Glucocorticoid use in preterm infants**

39
40 Systematic use of postnatal exogenous GC in PT infants for prevention of BPD
41
42 followed a 1994 publication of recommendations for prenatal GC administration to
43
44 reduce the likelihood of PT birth in women in PT labor (Noguchi, 2014). Subsequently,
45
46 in 2002, mounting evidence of neuromotor and cognitive impairment and impaired
47
48 cerebellar growth led the American Academy of Pediatrics (AAP) to recommend against
49
50 the use of postnatal GC (Committee on Fetus and Newborn, 2002). However, since
51
52 2010 and the publication of several studies of lower dose and lower potency GCs,
53
54 postnatal GC use has again increased. The most recent recommendations, published
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 in 2022, recommended against high dose dexamethasone (Cummings et al., 2022). No
5
6 recommendation was made regarding routine use of low potency steroids. Shared
7
8 decision making between clinicians and parents was recommended when deciding
9
10 whether to use steroids. In this state of clinical equipoise, additional information about
11
12 steroid effects on brain structure may help clinicians and families choose a treatment
13
14 path.
15
16
17
18

19 **1.2 Outcomes after post-natal glucocorticoid administration in preterm infants**

20
21 Studies of long-term neurodevelopmental outcomes after GC administration in
22
23 the neonatal period have been inconclusive regarding benefits and risks. Early studies
24
25 were generally limited by small sample sizes, underpowered to describe effects of GCs
26
27 on neurodevelopment and particularly to consider differences across different GCs,
28
29 such as dexamethasone and hydrocortisone (Doyle, 2021). A recent large multicenter
30
31 trial of over 800 infants failed to show benefit in decreasing BPD or improving survival
32
33 without moderate to severe disability (Watterberg et al., 2022). The accompanying
34
35 commentary suggested that research should adjust the dependent variables of interest
36
37 and consider the role of GC in the amelioration of severe respiratory disease rather than
38
39 in survival without BPD, as the primary measure of the utility of GC use (Greenough,
40
41
42
43
44
45
46
47 2022).

48 To overcome the limitations of individual studies, multiple systematic reviews
49
50 have considered the effects of GC administration and have made recommendations for
51
52 GC administration in preterm infants (Chang, 2014; Doyle et al., 2021a, 2021a;
53
54 Noguchi, 2014; Onland et al., 2017; Shah et al., 2017). These reviews focused on
55
56
57 several issues: clinical outcomes, including prevalence of BPD and later
58
59
60
61
62
63
64
65

1
2
3
4 neurodevelopmental outcomes, including neurodevelopmental disability; the optimal
5 administration plan for steroids; and the appropriate dose to maximize effectiveness
6 without incurring accompanying adverse effects. All these reviews concluded that
7 further research on long-term effects needs to be done. They recommended minimal
8 use of postnatal glucocorticoids, restricting treatment only to ventilator-dependent
9 infants, and limiting dose and duration. A review specifically of early GC administration
10 before 7 days of life concluded that the benefits of GCs (e.g. shorter ventilation time,
11 decreases in diagnosed BPD), may not outweigh the known risks (e.g. gastrointestinal
12 bleeding, cerebral palsy, hyperglycemia) (Doyle et al., 2021b). As a result, the review
13 recommended discontinuing the practice of early dexamethasone administration. A
14 separate review specifically of steroids started after day of life 7 found that the risk of
15 death and BPD was reduced without increased rates of cerebral palsy; however, the
16 long term effects had not been well studied (Doyle et al., 2021a). This review
17 demonstrated the importance of timing of GC administration.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 Concerning results were found in a review of specific steroid protocols (Onland et
39 al., 2017). This review noted increased risk of BPD and adverse neurodevelopmental
40 outcomes in children getting higher versus lower doses of GCs and no difference in
41 outcomes for early versus late administration. The studies however had important
42 methodological weaknesses and the review could not conclude with an optimal dose
43 regimen recommendation.
44
45
46
47
48
49
50
51
52

53 The reviews to date have not fully considered the effects of postnatal GCs on
54 developing brain structures, even though alternations in brain structure may be a major
55 contribution to adverse neurodevelopmental outcomes (Volpe, 2009). It remains
56
57
58
59
60
61
62
63
64
65

1
2
3
4 critically important to understand any impacts because changes may relate to later
5
6 neurodevelopmental outcomes. Indeed, structural brain findings may provide a proximal
7
8 indicator, available to clinicians while children born preterm are still hospitalized, of the
9
10 neurobiological effects of GCs, to inform clinical research and practice.
11
12

13 14 **1.3 Glucocorticoid effects on brain development**

15
16 Several lines of evidence support consideration of the effects of GC on brain
17
18 development in PT infants. GC enter the brain via simple diffusion across the blood
19
20 brain barrier. Within the brain, GC affect brain development via intracellular
21
22 glucocorticoid and mineralocorticoid receptors. Glucocorticoid receptor binding causes
23
24 both inhibition and enhancement of gene transcription (De Kloet et al., 1998; Nishi and
25
26 Kawata, 2007). Glucocorticoid receptor activation may suppress synaptic plasticity and
27
28 inhibit neuronal development. Glucocorticoid receptors are widely expressed in the glia
29
30 and neurons of the cerebrum and cerebellum (Bohn et al., 1994). Mineralocorticoid
31
32 receptor activation meanwhile may aid in synapse plasticity and neuronal survival
33
34 (Joëls, 2007; Johnston et al., 2009; McEwen, 1994; McEwen et al., 1992).
35
36 Mineralocorticoid receptors are primarily found in the hippocampus and limbic structures
37
38 (Joëls, 2001).
39
40
41
42
43
44

45
46 Age and sex affect distribution; prefrontal glucocorticoid receptor density
47
48 increases in childhood and expression in the hippocampus is higher in women than
49
50 men. Importantly, dexamethasone primarily binds glucocorticoid receptors, while
51
52 hydrocortisone additionally binds mineralocorticoid receptor (Reul et al., 2000),
53
54 suggesting that the impact on brain structure may vary as a function of which GC was
55
56 administered. The distinctive pharmacokinetic and pharmacodynamic profiles of
57
58
59
60
61
62
63
64
65

1
2
3
4 exogenous GC during childhood may result in increased exposure of central nervous
5
6 system tissue to exogenous glucocorticoids in children as compared to adults (Damsted
7
8 et al., 2011). Preterm infants may see even higher GC exposure in the brain than older
9
10 infants and children because of their permeable blood-brain barrier, reduced hepatic
11
12 metabolism and renal excretion, and lower protein binding capacity.
13
14

15
16 Animal studies provide additional evidence of potential effects of GC on infant
17
18 brains. Studies in neonatal rats have shown decreased neurogenesis, impaired long
19
20 term potentiation with dexamethasone, but not hydrocortisone. (Chang, 2014; Cotterrell
21
22 et al., 1972; Howard and Granoff, 1968; Huang et al., 1999). These neural changes
23
24 occurred along with behavioral abnormalities including delayed acquisition of motor
25
26 skills and impaired emotional control. Early treatment in rats (postnatal days 2-8) have
27
28 shown decreased hippocampal glucocorticoid receptor number at pubertal age
29
30 (postnatal day 40), suggesting lasting impacts on the regulation of cellular development
31
32 (Zoli et al., 1990). Adverse effects on CNS myelination have also been reported
33
34 (Gumbinas et al., 1973). The cerebellum appears to be especially sensitive to GC
35
36 exposure. Postnatal GC impair rat cerebellar development by decreasing cellular
37
38 proliferation (Noguchi, 2014). Cerebellar development is coordinated in a time sensitive
39
40 manner through proliferation of the extragranular layer, followed by a programmed,
41
42 endogenous GC-induced apoptosis of external granular layer cells. This process, when
43
44 induced too early by exogenous GC-administration, leads to impaired cerebellar
45
46 development. Similarly, studies of human infants demonstrated decreased cerebellar
47
48 volume after dexamethasone administration (Parikh NA et al., 2007; Tam et al., 2011).
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 Evidence of hydrocortisone effects on cerebellum were mixed, compared with
5
6 dexamethasone (Noguchi, 2014).
7

8 9 **1.4 Rationale for review of post-natal glucocorticoids on brain structures**

10
11 Given the diversity of the studies and multifactorial contributors to
12
13 neurodevelopmental outcomes, we sought to review the literature on a more proximal
14
15 and objective measure, structural brain metrics, to inform our understanding of the
16
17 effects of glucocorticoid administration on preterm brain development. We know that PT
18
19 infants show a particular pattern of brain injury and dysmaturity due to complex interplay
20
21 of developmental stage and medical intervention (Volpe, 2009). These brain changes
22
23 are now detectable using advanced imaging techniques and the differences are seen in
24
25 neurodevelopmental outcomes (Feldman et al., 2010). Several reviews have looked at
26
27 imaging studies and GC as part of an overall review of steroid effects on the neonatal
28
29 brain, the most recent of which are nearly 10 years old (Baud, 2004; Chang, 2014;
30
31 Favrais et al., 2014; Noguchi, 2014; Rademaker and de Vries, 2009). Given the
32
33 increase in imaging studies over the past decade, our aim was to review the current
34
35 literature. Because of the diversity of GC types, doses, timing, duration, and the
36
37 diversity of brain outcomes reported, a scoping review of the literature was most
38
39 appropriate. The primary objective of this scoping review is to identify what is known
40
41 about the effects of GC treatment on brain structural development in preterm human
42
43 infants with the goal of identifying gaps in the literature and potential intermediate
44
45 biomarker candidates for neurodevelopmental outcomes. With this review, we hope to
46
47 assess the scope of current research on the topic and identify future directions for
48
49 investigations of steroid administration and structural brain changes.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2.0 METHODS

We followed the Arksey and O'Malley methodological framework for scoping reviews to ensure an orderly approach to mapping the existing evidence on what is known broadly about this topic and to identify gaps in the literature (Arksey and O'Malley, 2005). The stages include: (1) identifying the research question; (2) identifying relevant studies; (3) selecting the studies; (4) charting the data; and (5) collating, summarizing, and reporting the results.

A search query was designed to yield articles that included 3 key topics: postnatal steroids, prematurity, and brain structure. We used a combination of MeSH terms and text word search of titles and abstracts. Our full search terms are shown in the **Supplement**. Using this strategy, we collected articles from ClinicalTrials.gov and PubMed published between January 1, 1990 and September 16, 2021. We also included references from recent Cochrane systematic reviews on postnatal glucocorticoid administration for preterm infants (Doyle et al., 2021a, 2021b; Onland et al., 2017).

The inclusion and exclusion criteria are shown in **Table 1**. We defined a structural brain outcome as description or measurement of one or more anatomical features, assessed using one or more neuroimaging modalities. For example, MRI was commonly used to report on overall and regional brain volumes or image slice area. Studies that reported on structural brain outcomes after postnatal GC administration to preterm children were our primary interest in this review. We differentiated the anatomical descriptions and measurements from general descriptions, such as intraventricular, brain parenchymal, and/or cerebellar hemorrhages or injuries, which

1
2
3
4 may or may not lead to variation in brain anatomy. These findings are frequently used to
5
6 characterize preterm study populations and are not necessarily treated as an outcome
7
8 of interest. We defined these outcomes as “brain injury”, reviewed them as a set, and, to
9
10 provide a comprehensive view of the literature, included these references in the
11
12 **Supplement**. Studies that included postnatal GC administration as a covariate or as a
13
14 possible risk factor moderating relations between preterm birth and brain structure, but
15
16 did not include information on GC type, dose, or administration were reviewed and also
17
18 included in the **Supplement**. We excluded Near Infrared Spectroscopy (NIRS) and
19
20 Doppler imaging modalities because they are considered functional modalities.
21
22
23
24
25

26 References were imported into Covidence (“Covidence systematic review
27
28 software,” n.d.) and were screened by 3 independent reviewers (IR, AE, SD) at each
29
30 step: title and abstract screening, full-text review, and data extraction. For title and
31
32 abstract screening, references were excluded only if it obviously met exclusion criteria,
33
34 such as being an animal study. For full-text review, articles were included if any
35
36 structural brain outcome was reported, regardless of it being a primary or secondary
37
38 outcome. The senior author (SD) reviewed and resolved conflicts when consensus
39
40 through discussion was not reached.
41
42
43
44

45 We extracted the following data from relevant studies: study design, aim of study,
46
47 trial name, cohort size, steroid administration (type, dose, route, duration), imaging
48
49 modality, primary and secondary outcomes, and brain outcome. For studies in the
50
51 supplement, the reported outcomes were not structural brain outcomes. For these
52
53 studies, we extracted the relevant brain data that were reported as a characteristic of
54
55 the study population following steroid exposure.
56
57
58
59
60
61
62
63
64
65

3.0 RESULTS

Using the criteria described in the methods, we identified 11 papers for inclusion in this review. A consort diagram is shown in the **Figure**. **Table 2** includes the studies that specifically examined structural brain outcomes as a result of GC exposure. An additional 62 studies were either glucocorticoid intervention trials that reported brain injury outcome (e.g. intraventricular hemorrhage, IVH) as a characteristic of the study population (n= 50), or were observational studies of brain structural outcomes that examined postnatal GC as a potential contributing or risk factor (n=12) and provided little or no information on glucocorticoid type or administration. These studies are summarized in the **Supplement**.

3.1 DEXAMETHASONE

Three studies reported on the association between dexamethasone exposure and a range of brain structural outcomes across a range of ages at the time of imaging. An early 3-D quantitative volumetric MRI study that imaged the participants at 38-41 weeks post conceptual age compared infants treated with dexamethasone to infants who were not exposed to GC and to term infants (Murphy BP et al., 2001). The dexamethasone-treated group was born at an earlier gestational age, had a longer length of stay, had higher clinical risk index for babies (CRIB) score in the first 12 hours of life. Cerebral cortical gray matter volume was reduced in the dexamethasone-exposed group compared with the non-exposed group, after adjusting for gestational age at birth and CRIB score (mean difference 65.3, 95% confidence interval: 4.3 to 114.58). There were

1
2
3
4 no significant cerebral cortical gray matter volume differences between non-exposed
5
6 preterm infants and control. Total cerebral tissue volume was reduced by 22% in the
7
8 dexamethasone treated versus non-treated preterm groups. After adjustment for
9
10 covariates, the volume remained lower, but was no longer statistically significant. No
11
12 differences were observed in the subcortical gray matter volumes (basal ganglia and
13
14 thalami). Myelinated white matter volume differed between preterm and full term
15
16 groups, but was not different between dexamethasone exposed and non-exposed
17
18 preterm infants. Unmyelinated white matter did not differ between groups.
19
20
21
22

23
24 Parikh and colleagues (Parikh NA et al., 2007) examined a later sample with
25
26 lower overall dexamethasone doses, adjusting for multiple potential confounders (PMA
27
28 at scan, dexamethasone treatment, birthweight, presence of BPD). They obtained
29
30 coronal T2 weighted MRI at a mean post menstrual age of 39.4 weeks. The authors
31
32 reported smaller total brain volumes (9.5%), cerebellar volumes (19.7%) and subcortical
33
34 gray matter volumes (20.6%) in the dexamethasone group. Total gray matter volume
35
36 was also lower in the dexamethasone group but did not meet statistical significance.
37
38 There was no dose response relationship between dexamethasone dose and total brain
39
40 volume and cortical tissue volume. To explain the smaller reductions seen compared
41
42 with Murphy et al. 2001, they pointed out that they used lower cumulative doses, later in
43
44 life, to higher risk ELBW infants, enrolled an unselected cohort, performed masked
45
46 evaluations, had a larger sample size, and adjusted for more potential confounders.
47
48
49
50
51

52
53 A third study obtained T1 weighted MRI at age 18 years in a cohort of individuals
54
55 born preterm who had received NICU administered dexamethasone. In this cohort, GC
56
57 were given at the discretion of the treating clinicians after the first week of life. The
58
59
60
61
62
63
64
65

1
2
3
4 dexamethasone group had a lower gestational age and birthweight and higher rates of
5
6 BPD and cerebral palsy than those who did not receive postnatal dexamethasone.
7
8 Overall they found a 3.6% (95% CI -7.0%, -0.3%) smaller total brain tissue volume at
9
10 age 18, that was not significantly different between groups after adjustment for
11
12 covariates. Volumes of total and most regional areas of cortical white matter, thalamus,
13
14 and basal ganglia nuclei were smaller in the dexamethasone group compared with the
15
16 no-dexamethasone group after adjustment for covariates. Unlike the studies reviewed
17
18 here which looked at scans from younger ages, there was no statistically significant
19
20 difference in cortical gray matter, hippocampus, amygdala, and cerebellar volumes.
21
22 Within white matter, on the other hand, the reduction in brain parcel volumes in the
23
24 dexamethasone group was found in most regions except the medial temporal region.
25
26 The authors hypothesized that the absence of cerebellar volume differences may have
27
28 been due to catch up cerebellar growth while the presence of white matter volume
29
30 reductions found in their study, which had not been reported previously, may reflect a
31
32 selective vulnerability of particular brain tissues and altered developmental trajectory
33
34 that is not detected until adolescence.
35
36
37
38
39
40
41
42

43 **3.2 HYDROCORTISONE**

44
45 Eight studies directly assessed the association between hydrocortisone and brain
46
47 structure. In 2005, Lodygensky et. al obtained 3D quantitative volumetric MRI in 8 year
48
49 old children who had been born preterm or full term (Lodygensky et al., 2005). A portion
50
51 of the PT children had received hydrocortisone due to respiratory illness severity. No
52
53 differences in 5 measures of brain volumes were seen between PT children who did or
54
55 did not receive neonatal hydrocortisone. This study reports that it is the first directly to
56
57
58
59
60
61
62
63
64
65

1
2
3
4 address the effect of postnatal corticosteroid treatment on hippocampal volumes in
5
6 humans. The authors hypothesized that the combination of the decreased potency and
7
8 shorter half-life of hydrocortisone compared with dexamethasone and hydrocortisone's
9
10 preferential binding of mineralocorticoid receptors versus dexamethasone's binding of
11
12 glucocorticoid receptors is protective.
13
14

15
16 A larger, overlapping study of the 8 year old children with the same 3D
17
18 quantitative volumetric MRI as Lodygensky study (Lodygensky et al., 2005) classified
19
20 MRI findings as normal, mildly abnormal, or severely abnormal and calculated corpus
21
22 callosum area on a midsagittal T2 slice. There were no differences in presence of brain
23
24 lesions on MRI between PT children who were treated with hydrocortisone and those
25
26 who were not after adjusting for a propensity score representing the likelihood of
27
28 requiring hydrocortisone. Mean midsagittal corpus callosum area was smaller in the
29
30 hydrocortisone treated group compared with the non-treated group, but the difference
31
32 was not significant after adjustment for the propensity score. No other brain differences
33
34 were identified. This investigation represented the largest group from their sample. In
35
36 addition to the potency and half-life of hydrocortisone vs dexamethasone, the authors
37
38 pointed to the use of sodium bisulphite as a preservative in dexamethasone as a
39
40 possible cause of decreased neuronal cell line viability based on in vitro and rodent
41
42 studies. They discussed the timing of glucocorticoid administration later in neonatal life
43
44 as potentially being beyond a particular window of developmental vulnerability.
45
46
47
48
49
50
51

52
53 Two studies reported on overlapping samples of PT infants with 3D volumetric
54
55 MRI at term equivalent age (Benders et al., 2009; Kersbergen et al., 2013). Benders
56
57 and colleagues performed a prospective study comparing infants who received a two-
58
59
60
61
62
63
64
65

1
2
3
4 week course of hydrocortisone at 1 week of life or later with age, gender, and
5
6 respiratory status matched controls from a second institution using the same MRI
7
8 scanner and the same imaging protocol. Adjusted analyses showed no differences
9
10 between groups for individual or summed volumes for the intracranial cavity, CSF,
11
12 cortical gray matter, subcortical gray matter, unmyelinated white matter, and myelinated
13
14 white matter. In the second investigation of an expanded cohort (Kersbergen et al.,
15
16 2013) there was no difference in total brain tissue volume between treated and
17
18 untreated controls after adjustment for covariates. Only post menstrual age at scan,
19
20 birthweight, and gestational age at birth were associated with total brain tissue volume.
21
22 This was the same whether hydrocortisone was treated as a continuous variable or high
23
24 vs low dose. They also looked at cerebellar volumes and found that while PMA at scan,
25
26 birth weight z score, and grade 3 IVH influenced cerebellar volumes, hydrocortisone did
27
28 not.
29
30
31
32
33
34
35

36 In a pilot randomized controlled trial, Parikh and colleagues obtained axial PD/T2
37
38 volumetric MRI scans at 38 weeks post menstrual age in infants randomized to
39
40 hydrocortisone or placebo with the specific objective of examining a structural brain
41
42 outcome (Parikh et al., 2013). Total brain tissue volume was the primary outcome.
43
44 Secondary brain outcomes included individual tissue volumes of cortical gray matter,
45
46 cerebral white matter, cerebrospinal fluid, subcortical gray matter and substructure
47
48 volumes of included nuclei, cerebellum, hippocampi, amygdalae, corpus callosum, and
49
50 brain stem. The study was powered to detect a 2-week growth difference in brain size.
51
52 In bivariate and adjusted analyses, total tissue volume was not different between the
53
54 groups. Secondary brain outcomes of regional volumes were not different between the
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 groups. The authors concluded that there were neither short term benefits or harms
5
6 from low dose hydrocortisone after the first week of life.
7

8
9 Allison et al. (Alison M et al., 2020) conducted a large predefined secondary
10 analysis of T1, T2, T2 GE MRI at term equivalent age of patients enrolled in the
11
12 PREMILOC trial of early hydrocortisone. A standardized scoring system was used to
13
14 evaluate cerebral WM, cortical and deep GM and cerebellar abnormalities. (Kidokoro et
15
16 al., 2013) A number of quantitative biometric values (sizes and areas of various
17
18 structures) were obtained. The primary endpoint was the occurrence of cerebral white
19
20 matter abnormalities. There were no differences in the cumulative distribution of white
21
22 matter scores between the treatment and control groups. Fewer infants born at 24-25
23
24 weeks in the hydrocortisone group developed dilated lateral ventricles compared with
25
26 the placebo group. The 24-25 week hydrocortisone group also had smaller lateral
27
28 ventricles than the placebo group. There were no differences in any of the cortical and
29
30 basal ganglia gray matter, nor cerebellar injury between the groups. There was no
31
32 difference in the distribution of the relevant scores between groups. There was a
33
34 statistically significant association between overall brain injury score cumulative
35
36 distribution between the groups, however hydrocortisone was no longer significantly
37
38 associated with white matter damage or overall moderate to severe brain damage after
39
40 adjustment for risk factors and gestational age.
41
42
43
44
45
46
47
48
49

50
51 Rousseau (Rousseau et al., 2021) obtained axial T2 MRI and aimed to explore
52
53 postnatal brain growth in extremely preterm born infants requiring postnatal steroids.
54
55 They examined brain tissue area at term equivalent age and head circumference growth
56
57 by 12 months of age. This report included children receiving hydrocortisone for any
58
59
60
61
62
63
64
65

1
2
3
4 indication (e.g., refractory hypotension, prolonged respiratory insufficiency).

5
6 Semiautomatic tissue segmentation was performed and areas of each tissue were
7
8 measured on an axial slice (not a 3D volumetric measurement). The study was powered
9
10 to see an 8% reduction of brain volumes at term equivalent age. Despite matching, the
11
12 hydrocortisone group was lower weight at birth and had more medical complications.
13
14 Adjusting for postmenstrual age at MRI scan, there was a significant reduction in the
15
16 intracranial cavity, the basal ganglia and thalamus area at term equivalent age. There
17
18 was no correlation between basal ganglia and thalamus (BGT) area and hydrocortisone
19
20 dose. Multiple regression showed that duration of mechanical ventilation was the only
21
22 significant independent variable associated with BGT (not with hydrocortisone
23
24 treatment).
25
26
27
28
29
30

31 **3.3 HYDROCORTISONE AND DEXAMETHASONE**

32
33 Tam and colleagues published a study focused on steroid effects on the
34
35 cerebrum and cerebellum that examined both hydrocortisone and dexamethasone (Tam
36
37 et al., 2011). They obtained T2-weighted and T1 3-D volumetric scans at two sites at
38
39 two time points – as soon after birth as the infant was able and again at term post
40
41 menstrual age. Adjusting for multiple covariates, there was a decrease in cerebellar
42
43 growth associated with glucocorticoid exposure resulting in 1.88 cm³ smaller cerebellum
44
45 at 40 weeks post menstrual age after hydrocortisone and 2.31 cm³ smaller cerebellum
46
47 associated with dexamethasone (8% and 10% smaller cerebellar volumes,
48
49 respectively). They were unable to determine whether there was a dose dependent
50
51 effect of glucocorticoids on cerebellar growth. Cerebellar volume was not associated
52
53 with the number of days since the last steroid administration, indicating that the volume
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 changes were not immediately reversible effects. Clinical factors were also associated
5
6 with decreased cerebellar volume including intubation duration, hypotension, patent
7
8 ductus arteriosus, but postnatal dexamethasone, postnatal hydrocortisone, and severe
9
10 intraventricular hemorrhage were associated with the largest decreases in cerebellar
11
12 volume. The same analyses were performed for cerebral volumes at term. Cerebral
13
14 volume at term was not associated with antenatal betamethasone exposure or with
15
16 postnatal hydrocortisone or dexamethasone exposure.
17
18
19
20
21
22

23 **3.4 INHALED GLUCOCORTICOIDS**

24
25
26 We identified no studies examining association between inhaled corticosteroids
27
28 in preterm infants and structural brain outcomes.
29
30
31
32

33 **4.0 DISCUSSION**

34
35
36 In this scoping review we identified 11 papers related to associations or effects
37
38 between postnatal GC and structural or anatomical brain metrics in humans born PT.
39
40 Dexamethasone was consistently associated with unfavorable brain differences.
41
42 Radiologist scoring rubrics and quantitative total and regional brain areas or volumes of
43
44 varied structures were reported. The results showed that for dexamethasone, exposure
45
46 to dexamethasone was associated with reduction in volumes across multiple brain
47
48 regions, including the cerebellum, and metrics. However, for hydrocortisone, only one
49
50 study has reported that exposure to medication was associated with volumetric
51
52 differences and these localized to the cerebellum. Overall cohort sizes varied from
53
54 small to large. The range of treatment dose, duration, and age at initiation varied widely.
55
56
57
58
59
60
61
62
63
64
65

4.1 STUDY TIMING

While most studies examined imaging obtained during the initial neonatal course, there were several reports on a cohort of 8-year-old children born preterm and one as late as 18 years of age. All of these time frames are important and relevant to understanding the potential long-term outcome of GC given during a sensitive developmental window. The case for using imaging during the neonatal hospital course is strong. Infant MRI metrics may serve as proximal biomarkers associated with later developmental outcomes. Having a predictive biomarker in the neonatal period can avoid the confounding of later post-NICU experience in understanding the effects of GC on brain. Future studies should assess advanced MRI metrics as mediators of GC effects on later neurodevelopmental outcomes. Evaluation at later ages is also important to understanding neurodevelopment. The preterm newborn brain undergoes rapid development. Glucocorticoids in the neonatal period act on a changing substrate. Effects may not be evident until the brain structure is more mature. Furthermore, the timing of glucocorticoid administration during the neonatal period could produce different effects on brain structure and development.

4.2 MEASUREMENT CHOICE

In the clinical setting, a measure should be objective, easily obtained, relevant to the exposure and the later outcome it relates to. Because of the differing GR and MR receptor distribution in the brain, examining subregions or certain types of brain matter (e.g. white vs gray matter; cerebral vs cerebellar), may better identify effects than a whole brain approach. Although not routinely implemented in the clinical setting, no

1
2
3
4 study has yet examined effects of GC using advanced microstructural metrics, for
5
6 instance diffusion metrics (Feldman et al., 2010) or quantitative microstructural metrics
7
8 (Mancini et al., 2020). These metrics may get closer to the underlying neurobiology and
9
10 therefore may detect GC effects that cannot be seen on the more macroscopic
11
12 volumetric scale that has been reported thus far. Using these quantitative metrics may
13
14 shed light on contradictory results from the macroscopic volumetric measures.
15
16
17
18

19 **4.3 CHALLENGES IN CONDUCTING AND COMPARING STUDIES**

20
21 This review highlights the difficulty of conducting and comparing randomized
22
23 trials of steroids in preterm infants. Some studies were found not to be feasible due to
24
25 difficulty with patient recruitment. Studies were stopped, and dosing changed midway.
26
27 Most of the studies reporting on brain structure were small or of modest size. Changes
28
29 in clinical practice over time make comparison across studies challenging. The larger
30
31 studies often had a range of GC doses and regimens. While multicenter RCTs should
32
33 incorporate brain metrics into their study design, we should also consider how
34
35 prospective or retrospective cohorts can account for heterogeneity in treatment and
36
37 sample size limitations to leverage the power of modern electronic health records in
38
39 asking clinical questions such as those relating to GC use. Rousseau (Rousseau C et
40
41 al., 2021) for instance investigated correlations between dose and brain area, while
42
43 Kersbergen (Kersbergen et al., 2013) looked at both continuous and high/low
44
45 measures. Tam et. al. employed several strategies for analyzing cohort data (Tam et al.,
46
47 2011). The multi-site study was able to collect a large sample. They were the only
48
49 study to examine brain imaging longitudinally, strengthening the causal argument. They
50
51 examined regional brain volumes, and they attempted to assess dose response. Their
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 results have not been reproduced, although it is difficult to directly compare studies
5
6 because of the analytic complexities discussed here. Collaboration and continued
7
8 research with more current datasets will be important to understanding the safety and
9
10 effectiveness of GC treatments in preterm infants.
11
12
13
14

15 16 **5.0 CONCLUSIONS**

17
18
19 GC effects on brain are of interest to a wide audience of researchers across the
20
21 lifespan and across many clinical conditions. Despite the availability of clinical and
22
23 research advanced imaging modalities, relatively few human studies have directly
24
25 assessed the effect of this intervention on brain structural development. This review
26
27 highlights the need for additional research on neonatal GC and their potential effects on
28
29 brain development. As GC use becomes more targeted and ongoing research aims to
30
31 identify optimal populations and treatment regimens, incorporating information about
32
33 both brain structure in the infant period and in later childhood can provide researchers
34
35 and clinicians with a better understanding of the downstream effects of this important
36
37 treatment on neurodevelopment.
38
39
40
41
42
43
44

45
46 **ACKNOWLEDGEMENTS:** This work was supported by the National Institutes of Health
47
48 (2RO1- HD069150) and the Young Investigator Award to Dr. Dubner, from the Society of
49
50 Developmental and Behavioral Pediatrics (2019).
51
52
53
54
55

56 **REFERENCES**

57 Alison M, Tilea B, Toumazi A, Biran V, Mohamed D, Alberti C, Bourmaud A, Baud O, 2020.
58 Prophylactic hydrocortisone in extremely preterm infants and brain MRI abnormality.
59
60
61
62
63
64
65

- 1
2
3
4 Arch Dis Child Fetal Neonatal Ed 105, 520–525. <https://doi.org/10.1136/archdischild-2019-317720>
- 5
6
7 Arksey, H., O'Malley, L., 2005. Scoping studies: towards a methodological framework.
8 International Journal of Social Research Methodology 8, 19–32.
9 <https://doi.org/10.1080/1364557032000119616>
- 10
11 Baud, O., 2004. Postnatal steroid treatment and brain development. Arch Dis Child Fetal
12 Neonatal Ed 89, F96–F100. <https://doi.org/10.1136/adc.2003.028696>
- 13
14 Benders, M.J.N.L., Groenendaal, F., van Bel, F., Ha Vinh, R., Dubois, J., Lazeyras, F., Warfield,
15 S.K., Hüppi, P.S., de Vries, L.S., 2009. Brain development of the preterm neonate after
16 neonatal hydrocortisone treatment for chronic lung disease. Pediatr. Res. 66, 555–559.
17 <https://doi.org/10.1203/PDR.0b013e3181b3aec5>
- 18
19 Bohn, M.C., O'Banion, M.K., Young, D.A., Giuliano, R., Hussain, S., Dean, D.O., Cunningham, L.A.,
20 1994. In vitro studies of glucocorticoid effects on neurons and astrocytes. Annals of the
21 New York Academy of Sciences 746, 243–258. <https://doi.org/10.1111/j.1749-6632.1994.tb39241.x>
- 22
23
24 Chang, Y.P., 2014. Evidence for adverse effect of perinatal glucocorticoid use on the developing
25 brain. Korean J Pediatr 57, 101–109. <https://doi.org/10.3345/kjp.2014.57.3.101>
- 26
27 Committee on Fetus and Newborn, 2002. Postnatal Corticosteroids to Treat or Prevent Chronic
28 Lung Disease in Preterm Infants. Pediatrics 109, 330–338.
29 <https://doi.org/10.1542/peds.109.2.330>
- 30
31 Cotterrell, M., Balázs, R., Johnson, A.L., 1972. Effects of corticosteroids on the biochemical
32 maturation of rat brain: postnatal cell formation. J Neurochem 19, 2151–2167.
33 <https://doi.org/10.1111/j.1471-4159.1972.tb05124.x>
- 34
35 Covidence systematic review software, n.d.
- 36
37 Cummings, J.J., Pramanik, A.K., COMMITTEE ON FETUS AND NEWBORN, 2022. Postnatal
38 Corticosteroids to Prevent or Treat Chronic Lung Disease Following Preterm Birth.
39 Pediatrics e2022057530. <https://doi.org/10.1542/peds.2022-057530>
- 40
41 Damsted, S.K., Born, A.P., Paulson, O.B., Uldall, P., 2011. Exogenous glucocorticoids and adverse
42 cerebral effects in children. Eur J Paediatr Neurol 15, 465–477.
43 <https://doi.org/10.1016/j.ejpn.2011.05.002>
- 44
45 De Kloet, E.R., Vreugdenhil, E., Oitzl, M.S., Joëls, M., 1998. Brain corticosteroid receptor balance
46 in health and disease. Endocr Rev 19, 269–301. <https://doi.org/10.1210/edrv.19.3.0331>
- 47
48 Doyle, L.W., 2021. Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia.
49 NEO 118, 244–251. <https://doi.org/10.1159/000515950>
- 50
51 Doyle, L.W., Cheong, J.L.Y., Hay, S., Manley, B.J., Halliday, H.L., 2021a. Late (≥ 7 days) systemic
52 postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm
53 infants. Cochrane Database of Systematic Reviews.
54 <https://doi.org/10.1002/14651858.CD001145.pub5>
- 55
56 Doyle, L.W., Cheong, J.L.Y., Hay, S., Manley, B.J., Halliday, H.L., 2021b. Early (< 7 days) systemic
57 postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm
58 infants. Cochrane Database of Systematic Reviews.
- 59
60 Favrais, G., Tourneux, P., Lopez, E., Durrmeyer, X., Gascoïn, G., Ramful, D., Zana-Taieb, E., Baud,
61 O., 2014. Impact of common treatments given in the perinatal period on the developing
62 brain. Neonatology 106, 163–172. <https://doi.org/10.1159/000363492>
- 63
64
65

- 1
2
3
4 Feldman, H.M., Yeatman, J.D., Lee, E.S., Barde, L.H., Gaman-Bean, S., 2010. Diffusion tensor
5 imaging: a review for pediatric researchers and clinicians. *Journal of developmental and*
6 *behavioral pediatrics* : JDBP 31, 346–56.
7 <https://doi.org/10.1097/DBP.0b013e3181dcaa8b>
8
9 Gallini, F., Coppola, M., De Rose, D.U., Maggio, L., Arena, R., Romano, V., Cota, F., Ricci, D.,
10 Romeo, D.M., Mercuri, E.M., Vento, G., 2021. Neurodevelopmental outcomes in very
11 preterm infants: The role of severity of Bronchopulmonary Dysplasia. *Early Human*
12 *Development* 152, 105275. <https://doi.org/10.1016/j.earlhumdev.2020.105275>
13
14 Greenough, A., 2022. Hydrocortisone to Prevent Bronchopulmonary Dysplasia — Not a Silver
15 Bullet. *New England Journal of Medicine* 386, 1181–1183.
16 <https://doi.org/10.1056/NEJMe2200247>
17
18 Gumbinas, M., Oda, M., Huttenlocher, P., 1973. The effects of corticosteroids on myelination of
19 the developing rat brain. *Biol Neonate* 22, 355–366. <https://doi.org/10.1159/000240568>
20
21 Howard, E., Granoff, D.M., 1968. Increased voluntary running and decreased motor
22 coordination in mice after neonatal corticosterone implantation. *Exp Neurol* 22, 661–
23 673. [https://doi.org/10.1016/0014-4886\(68\)90155-6](https://doi.org/10.1016/0014-4886(68)90155-6)
24
25 Huang, W.L., Dunlop, S.A., Harper, C.G., 1999. Effect of Exogenous Corticosteroids on the
26 Developing Central Nervous System: A Review. *Obstetrical & Gynecological Survey* 54,
27 336–342.
28
29 Joëls, M., 2007. Role of corticosteroid hormones in the dentate gyrus. *Progress in Brain*
30 *Research* 163, 355–370. [https://doi.org/10.1016/S0079-6123\(07\)63021-0](https://doi.org/10.1016/S0079-6123(07)63021-0)
31
32 Joëls, M., 2001. Corticosteroid actions in the hippocampus. *Journal of Neuroendocrinology* 13,
33 657–669. <https://doi.org/10.1046/j.1365-2826.2001.00688.x>
34
35 Johnston, M.V., Ishida, A., Ishida, W.N., Matsushita, H.B., Nishimura, A., Tsuji, M., 2009.
36 Plasticity and injury in the developing brain. *Brain and Development* 31, 1–10.
37 <https://doi.org/10.1016/j.braindev.2008.03.014>
38
39 Kersbergen, K.J., de Vries, L.S., van Kooij, B.J.M., Işgum, I., Rademaker, K.J., van Bel, F., Hüppi,
40 P.S., Dubois, J., Groenendaal, F., Benders, M.J.N.L., 2013. Hydrocortisone treatment for
41 bronchopulmonary dysplasia and brain volumes in preterm infants. *J. Pediatr.* 163, 666-
42 671.e1. <https://doi.org/10.1016/j.jpeds.2013.04.001>
43
44 Kidokoro, H., Neil, J.J., Inder, T.E., 2013. New MR imaging assessment tool to define brain
45 abnormalities in very preterm infants at term. *AJNR Am J Neuroradiol* 34, 2208–2214.
46 <https://doi.org/10.3174/ajnr.A3521>
47
48 Lodygensky, G.A., Rademaker, K., Zimine, S., Gex-Fabry, M., Lieftink, A.F., Lazeyras, F.,
49 Groenendaal, F., de Vries, L.S., Hüppi, P.S., 2005. Structural and functional brain
50 development after hydrocortisone treatment for neonatal chronic lung disease.
51 *Pediatrics* 116, 1–7. <https://doi.org/10.1542/peds.2004-1275>
52
53 Mancini, M., Karakuzu, A., Cohen-Adad, J., Cercignani, M., Nichols, T.E., Stikov, N., 2020. An
54 interactive meta-analysis of MRI biomarkers of myelin. *Elife* 9, e61523.
55 <https://doi.org/10.7554/eLife.61523>
56
57 McEwen, B.S., 1994. Corticosteroids and Hippocampal Plasticity. *Annals of the New York*
58 *Academy of Sciences* 746, 134–142. [https://doi.org/10.1111/j.1749-](https://doi.org/10.1111/j.1749-6632.1994.tb39223.x)
59 [6632.1994.tb39223.x](https://doi.org/10.1111/j.1749-6632.1994.tb39223.x)
60
61
62
63
64
65

- 1
2
3
4 McEwen, B.S., Angulo, J., Cameron, H., Chao, H.M., Daniels, D., Gannon, M.N., Gould, E.,
5 Mendelson, S., Sakai, R., Spencer, R., Woolley, C., 1992. Paradoxical effects of adrenal
6 steroids on the brain: Protection versus degeneration. *Biological Psychiatry* 31, 177–199.
7 [https://doi.org/10.1016/0006-3223\(92\)90204-D](https://doi.org/10.1016/0006-3223(92)90204-D)
8
9
10 Ment, L.R., Hirtz, D., Hüppi, P.S., 2009. Imaging biomarkers of outcome in the developing
11 preterm brain. *The Lancet Neurology* 8, 1042–1055. [https://doi.org/10.1016/S1474-](https://doi.org/10.1016/S1474-4422(09)70257-1)
12 [4422\(09\)70257-1](https://doi.org/10.1016/S1474-4422(09)70257-1)
13
14 Murphy BP, Inder TE, Huppi PS, Warfield S, Zientara GP, Kikinis R, Jolesz FA, Volpe JJ, 2001.
15 Impaired cerebral cortical gray matter growth after treatment with dexamethasone for
16 neonatal chronic lung disease. *Pediatrics* 107, 217–21.
17 <https://doi.org/10.1542/peds.107.2.217>
18
19 Nishi, M., Kawata, M., 2007. Dynamics of glucocorticoid receptor and mineralocorticoid
20 receptor: Implications from live cell imaging studies. *Neuroendocrinology* 85, 186–192.
21 <https://doi.org/10.1159/000101917>
22
23 Noguchi, K.K., 2014. Glucocorticoid Induced Cerebellar Toxicity in the Developing Neonate:
24 Implications for Glucocorticoid Therapy during Bronchopulmonary Dysplasia. *Cells* 3,
25 36–52. <https://doi.org/10.3390/cells3010036>
26
27 Onland, W., De Jaegere, A.P., Offringa, M., van Kaam, A., 2017. Systemic corticosteroid
28 regimens for prevention of bronchopulmonary dysplasia in preterm infants. *Cochrane*
29 *Database of Systematic Reviews*. <https://doi.org/10.1002/14651858.CD010941.pub2>
30
31 Parikh, N.A., Kennedy, K.A., Lasky, R.E., McDavid, G.E., Tyson, J.E., 2013. Pilot randomized trial
32 of hydrocortisone in ventilator-dependent extremely preterm infants: effects on
33 regional brain volumes. *J. Pediatr.* 162, 685-690.e1.
34 <https://doi.org/10.1016/j.jpeds.2012.09.054>
35
36 Parikh NA, Lasky RE, Kennedy KA, Moya FR, Hochhauser L, Romo S, Tyson JE, 2007. Postnatal
37 dexamethasone therapy and cerebral tissue volumes in extremely low birth weight
38 infants. *Pediatrics* 119, 265–72. <https://doi.org/10.1542/peds.2006-1354>
39
40 Patra, A., Huang, H., Bauer, J.A., Giannone, P.J., 2017. Neurological consequences of systemic
41 inflammation in the premature neonate. *Neural Regen Res* 12, 890–896.
42 <https://doi.org/10.4103/1673-5374.208547>
43
44 Rademaker, K.J., de Vries, W.B., 2009. Long-term effects of neonatal hydrocortisone treatment
45 for chronic lung disease on the developing brain and heart. *Seminars in Fetal and*
46 *Neonatal Medicine, Uses and Abuses of Corticosteroids* 14, 171–177.
47 <https://doi.org/10.1016/j.siny.2008.11.004>
48
49 Reul, J.M.H.M., Gesing, A., Droste, S., Stec, I.S.M., Weber, A., Bachmann, C., Bilanz-Bleuel, A.,
50 Holsboer, F., Linthorst, A.C.E., 2000. The brain mineralocorticoid receptor: Greedy for
51 ligand, mysterious in function. *European Journal of Pharmacology* 405, 235–249.
52 [https://doi.org/10.1016/S0014-2999\(00\)00677-4](https://doi.org/10.1016/S0014-2999(00)00677-4)
53
54 Rousseau, C., Guichard, M., Saliba, E., Morel, B., Favrais, G., 2021. Duration of mechanical
55 ventilation is more critical for brain growth than postnatal hydrocortisone in extremely
56 preterm infants. *Eur J Pediatr* 180, 3307–3315. [https://doi.org/10.1007/s00431-021-](https://doi.org/10.1007/s00431-021-04113-z)
57 [04113-z](https://doi.org/10.1007/s00431-021-04113-z)
58
59
60
61
62
63
64
65

- 1
2
3
4 Rousseau C, Guichard M, Saliba E, Morel B, Favrais G, 2021. Duration of mechanical ventilation
5 is more critical for brain growth than postnatal hydrocortisone in extremely preterm
6 infants. *Eur J Pediatr*. <https://doi.org/10.1007/s00431-021-04113-z>
7
8 Shah, S.S., Ohlsson, A., Halliday, H.L., Shah, V.S., 2017. Inhaled versus systemic corticosteroids
9 for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm
10 neonates. *Cochrane Database of Systematic Reviews*.
11 <https://doi.org/10.1002/14651858.CD002058.pub3>
12
13 Tam, E.W.Y., Chau, V., Ferriero, D.M., Barkovich, A.J., Poskitt, K.J., Studholme, C., Fok, E.D.-Y.,
14 Grunau, R.E., Glidden, D.V., Miller, S.P., 2011. Preterm cerebellar growth impairment
15 after postnatal exposure to glucocorticoids. *Sci Transl Med* 3, 105ra105.
16 <https://doi.org/10.1126/scitranslmed.3002884>
17
18 Volpe, J.J., 2009. Brain injury in premature infants: a complex amalgam of destructive and
19 developmental disturbances. *Lancet Neurol* 8, 110–24. [https://doi.org/10.1016/S1474-](https://doi.org/10.1016/S1474-4422(08)70294-1)
20 [4422\(08\)70294-1](https://doi.org/10.1016/S1474-4422(08)70294-1)
21
22 Watterberg, K.L., Walsh, M.C., Li, L., Chawla, S., D’Angio, C.T., Goldberg, R.N., Hintz, S.R.,
23 Laughon, M.M., Yoder, B.A., Kennedy, K.A., McDavid, G.E., Backstrom-Lacy, C., Das, A.,
24 Crawford, M.M., Keszler, M., Sokol, G.M., Poindexter, B.B., Ambalavanan, N., Hibbs,
25 A.M., Truog, W.E., Schmidt, B., Wyckoff, M.H., Khan, A.M., Garg, M., Chess, P.R.,
26 Reynolds, A.M., Moallem, M., Bell, E.F., Meyer, L.R., Patel, R.M., Van Meurs, K.P.,
27 Cotten, C.M., McGowan, E.C., Hines, A.C., Merhar, S., Peralta-Carcelen, M., Wilson-
28 Costello, D.E., Kilbride, H.W., DeMauro, S.B., Heyne, R.J., Mosquera, R.A., Natarajan, G.,
29 Purdy, I.B., Lowe, J.R., Maitre, N.L., Harmon, H.M., Hogden, L.A., Adams-Chapman, I.,
30 Winter, S., Malcolm, W.F., Higgins, R.D., 2022. Hydrocortisone to Improve Survival
31 without Bronchopulmonary Dysplasia. *N Engl J Med* 386, 1121–1131.
32 <https://doi.org/10.1056/NEJMoa2114897>
33
34 Zoli, M., Agnati, L.F., Fuxe, K., Ferraguti, F., Biagini, G., Cintra, A., Gustafsson, J.A., 1990. Long-
35 lasting reduction of glucocorticoid receptor immunoreactivity in the hippocampal field
36 CA1 but not in the dentate gyrus after neonatal treatment with corticosterone in the
37 rat. *Acta Physiol Scand* 138, 577–579. [https://doi.org/10.1111/j.1748-](https://doi.org/10.1111/j.1748-1716.1990.tb08887.x)
38 [1716.1990.tb08887.x](https://doi.org/10.1111/j.1748-1716.1990.tb08887.x)
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .



FIGURE. Consort diagram of studies screened and extracted.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

TABLES

Table 1. Inclusion and exclusion criteria for title and abstract review

Inclusion Criteria	Exclusion Criteria
1. Papers from 1990 and later	1. Conference abstracts, case studies/reports if less than 10 subjects, dissertations; review papers; preprints; theoretical papers
2. English language	2. Endogenous GC exposure or measurement
3. Published and peer-reviewed	3. GCs administered antenatally only
4. Contains empirical data	4. No structural brain outcomes reported
5. Human subjects	5. Functional brain imaging studies only
6. Infants born before 37 weeks gestation	6. Animal study with no human participants
7. Postnatal exogenous GC exposure	7. Topical GC application only
8. GCs administered systemically - enteral, intravenous, intramuscular, inhaled, nebulized, intranasally administered, sublingual, or subcutaneous	8. GCs after birth hospitalization discharge
9. GCs administered to infants during birth hospitalization	
10. At least one structural brain outcome measured after GC administration	

Table 2. Studies of glucocorticoids and brain structure in preterm born infants

Steroid	Author Year	Study Type	Number of Participants	Administration Details	Age at Imaging	Structural Brain Outcomes	Effect
DEXAMETHASONE	Cheong 2014 ¹	Cohort Study	GC: 55 No GC: 93	7.9 ± 4.0 mg/kg for median duration 27d 17-39 either parenterally or orally.	18 years	Total and regional volumes, hippocampal volume	Reduced brain volume
	Murphy 2001 ²	Cohort Study	GC: 7 No GC: 11 Term Infants: 14	Median dose of 0.25 (0.19-0.90) mg/kg/d. With a mean duration of 28d (6-57). Age at first dose: 5 of 7 started in the first 14d of life.	38-41 weeks post conceptual age	Cortical gray matter, cerebral tissue	Reduced brain volume
	Parikh 2007 ³	Cohort Study	GC: 11 No GC: 30	Mean cumulative dose of 2.8 (1.2-5.9) mg/kg. With a mean duration of 6.8d (2-14). Orally or injected. Age at first dose: 28d.	GC: mean: 41.7 weeks post menstrual age; SD: 3.8 weeks No GC: mean: 38.7 weeks post menstrual age; SD: 2.4 weeks	Total brain, cerebellum	Reduced brain volume
HYDROCORTISONE	Alison 2020 ⁴	RCT	GC: 148 No GC: 147	1mg/kg/d divided into 2 doses for 7d. 0.5 mg/kg/d for 3d, intravenously.	"Term Equivalent Age"	Kidokoro scoring of cerebral white matter, cortical and deep gray matter, and cerebellar abnormalities; lateral ventricular diameter, biparietal width, interhemispheric distance, deep gray matter area, transcerebellar diameter, vermian height and diameter	No association
	Benders 2009 ⁵	Cohort Study	GC: 19 No GC: 19	5 mg/kg/d divided into 4 doses for 1 week, followed by a tapering course of 3, 2, and 1 dose(s) every 5d. Total dose: 3.75, 2.5, and 1.25 mg/kg/d. Age at first dose: 14d (7-44)	GC: mean: 41.1 weeks post menstrual age; SD: 0.8 weeks No GC: mean: 40.8 weeks post menstrual	Total cerebral tissue and intracranial volume	No association

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

					age; SD: 1.0 weeks		
	Kersbergen 2013 ⁶	Cohort Study	GC: 73 No GC: 73	5 mg/kg/d divided into 4 doses for 1 week and a subsequent tapering course every 5d. Total cumulative dose: 72.5 mg/kg over 22 days. Age at first dose: >7d postnatal age	GC: mean: 41.1 weeks post menstrual age; SD: 0.8 weeks No GC: mean: 41.1 weeks post menstrual age; SD: 0.8 weeks	Total brain tissue and cerebellar volume	No association
	Lodygensky 2005 ⁷	Cohort Study	GC: 23 No GC: 35 Healthy Term: 21	5 mg/kg/d, 4 doses for the first week, followed by a taper (not reported). Median age at first dose: 18d (4-43).	Mean: 8 years 7 months, SD: 8.6 months	Gray matter, white matter, hippocampal volumes	No association
	Parikh 2013 ⁸	RCT	GC: 31 No GC: 33	3mg/kg/d q12hrs for 4d, 2mg/kg/d for 2 days, then 1mg/kg/d for 1 day. Total cumulative dose of 17 mg/kg, intravenously. Age at first dose: not reported. At least 7d.	38 weeks post menstrual age	Total brain tissue volume	No association
	Rademaker 2007 ⁹	Cohort Study	GC: 62 No GC: 164	5 mg/kg/d, divided into 4 doses for 1 week. Followed by a tapering course of 3, 2, and 1 dose(s) each for 5D (total of 3.75, 2.5, and 1.25 mg/kg/d, respectively). Median duration: 27.5d (IQR, 12d). Age at first dose: >1 week of postnatal age.	Median 8.1 years	MRI lesions at school age classified as normal, mildly abnormal, severely abnormal; corpus callosum area on a midsagittal T2	No association
	Rousseau 2021	Cohort Study	GC 20 No GC: 40	for refractory arterial hypotension: 6-12 mg/kg/d. for life-threatening respiratory insufficiency/prolonged mechanical ventilation beyond 21st day of life: 5 mg/kg/d.	GC: mean: 40 weeks post menstrual age (37 weeks 0 days – 48 weeks 6 days) No GC: mean: 40 weeks post	basal ganglia and thalamus area	No association

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

				median duration of treatment was 8d. Median age of treatment was 12d old for hemodynamic indications (n = 7) and 27d old for respiratory indications (n = 16).	menstrual age (37 weeks 4 days – 45 weeks 5 days)	
HC or DEX	Tam 2011 ¹¹ Cohort Study	Site 1: 57 subjects (92 scans) Site 2: 115 subjects (206 scans)	HC: 1-3 mg/kg/d followed by tapering daily doses. DEX: 0.15mg/kg/d followed by tapering daily doses for BPD or 0.15mg/kg/dose for up to 3 doses prior to extubation for airway edema.	Site 1: first scan mean 31.7, SD 1.6 weeks post menstrual age. Second scan mean: 35.7, SD 2.2 weeks post menstrual age. Site 2: first scan mean 32.3, SD 3.3 weeks post menstrual age. Second scan mean 40.5, SD 2.9 weeks post menstrual age	Cerebellar volumes	Impaired cerebellar growth

Abbreviations: HC Hydrocortisone, DEX dexamethasone, RCT randomized controlled trial, BPD bronchopulmonary dysplasia

¹Cheong JL, Burnett AC, Lee KJ, Roberts G, Thompson DK, Wood SJ, Connelly A, Anderson PJ, Doyle LW, 2014. Association between postnatal dexamethasone for treatment of bronchopulmonary dysplasia and brain volumes at adolescence in infants born very preterm. *J Pediatr* 164, 737-743.e1.

²Murphy BP, Inder TE, Huppi PS, Warfield S, Zientara GP, Kikinis R, Jolesz FA, Volpe JJ, 2001. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. *Pediatrics* 107, 217–21. <https://doi.org/10.1542/peds.107.2.217>

³Parikh NA, Lasky RE, Kennedy KA, Moya FR, Hochhauser L, Romo S, Tyson JE, 2007. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. *Pediatrics* 119, 265–72. <https://doi.org/10.1542/peds.2006-1354>

⁴Alison M, Tilea B, Toumazi A, Biran V, Mohamed D, Alberti C, Bourmaud A, Baud O, 2020. Prophylactic hydrocortisone in extremely preterm infants and brain MRI abnormality. *Arch Dis Child Fetal Neonatal Ed* 105, 520–525. <https://doi.org/10.1136/archdischild-2019-317720>

⁵Benders MJ, Groenendaal F, van Bel F, Ha Vinh R, Dubois J, Lazeyras F, Warfield SK, Hüppi PS, de Vries LS, 2009. Brain development of the preterm neonate after neonatal

1
2
3
4 hydrocortisone treatment for chronic lung disease. *Pediatr Res* 66, 555–9.

5 <https://doi.org/10.1203/PDR.0b013e3181b3aec5>

6
7⁶Kersbergen KJ, de Vries LS, van Kooij BJ, Išgum I, Rademaker KJ, van Bel F, Hüppi PS,
8 Dubois J, Groenendaal F, Benders MJ, 2013. Hydrocortisone treatment for
9 bronchopulmonary dysplasia and brain volumes in preterm infants. *J Pediatr* 163, 666–
10 71.e1. <https://doi.org/10.1016/j.jpeds.2013.04.001>

11
12⁷Lodygensky GA, Rademaker K, Zimine S, Gex-Fabry M, Lieftink AF, Lazeyras F, Groenendaal
13 F, de Vries LS, Hüppi PS, 2005. Structural and functional brain development after
14 hydrocortisone treatment for neonatal chronic lung disease. *Pediatrics* 116, 1–7.
15 <https://doi.org/10.1542/peds.2004-1275>

16
17⁸Parikh NA, Kennedy KA, Lasky RE, McDavid GE, Tyson JE, 2013. Pilot randomized trial of
18 hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional
19 brain volumes. *J Pediatr* 162, 685-690.e1. <https://doi.org/10.1016/j.jpeds.2012.09.054>

20
21⁹Rademaker KJ, Uiterwaal CS, Groenendaal F, Venema MM, van Bel F, Beek FJ, van Haastert
22 IC, Grobbee DE, de Vries LS, 2007. Neonatal hydrocortisone treatment:
23 neurodevelopmental outcome and MRI at school age in preterm-born children. *J Pediatr*
24 150, 351–7. <https://doi.org/10.1016/j.jpeds.2006.10.051>

25
26¹⁰Rousseau C, Guichard M, Saliba E, Morel B, Favrais G, 2021. Duration of mechanical
27 ventilation is more critical for brain growth than postnatal hydrocortisone in extremely
28 preterm infants. *Eur J Pediatr*. <https://doi.org/10.1007/s00431-021-04113-z>

29
30¹¹Tam EW, Chau V, Ferriero DM, Barkovich AJ, Poskitt KJ, Studholme C, Fok ED, Grunau RE,
31 Glidden DV, Miller SP, 2011. Preterm cerebellar growth impairment after postnatal
32 exposure to glucocorticoids. *Sci Transl Med* 3, 105ra105.
33 <https://doi.org/10.1126/scitranslmed.3002884>

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

SUPPLEMENTAL MATERIAL

S1. Full Search Term for PubMed

("infant, newborn"[MeSH Terms] OR "infan*"[Text Word] OR "neonat*"[Text Word] OR "newborn*"[Text Word] OR "premature"[Text Word] OR "low birth weight"[Text Word] OR "VLBW"[Text Word] OR "LBW"[Text Word] OR "ELBW"[Text Word] OR ("Premature birth"[MeSH Terms] OR "infant, premature"[MeSH Terms] OR "infant, very low birth weight"[MeSH Terms] OR "infant, premature, diseases"[MeSH Terms] OR ("preterm"[Text Word] OR "premature"[Text Word] OR "Prematurity"[Text Word] OR "prematurely"[Text Word]) AND ("deliver*"[Text Word] OR "birth*"[Text Word] OR "infant*"[Text Word] OR "infancy"[Text Word] OR "baby"[Text Word] OR "babies"[Text Word] OR "neonat*"[Text Word] OR "newborn*"[Text Word] OR "perinatal"[Text Word] OR "parturition"[Text Word])) OR "preemi*"[Text Word] OR "premi"[Text Word] OR "premie"[Text Word] OR "premies"[Text Word] OR "preterm"[Text Word] OR "low birth weight"[Text Word] OR "low birthweight"[Text Word] OR "early gestation*"[Text Word] OR "low gestation*"[Text Word])) AND ("Brain"[MeSH Terms] OR "Brain"[Text Word] OR "nerve fibers, myelinated"[MeSH Terms] OR "white matter*"[Text Word] OR "myelinated nerve fiber*"[Text Word] OR "Glia"[Text Word] OR "gray matter"[Text Word] OR "cerebel*"[Text Word] OR "ventric*"[Text Word] OR "cerebrum"[Text Word] OR "corpus callosum"[Text Word] OR "internal capsules"[Text Word] OR "external capsules"[Text Word] OR "anterior commissure"[Text Word] OR "limbic system"[Text Word]) AND ("hydrocortisone"[MeSH Terms] OR "dexamethasone"[MeSH Terms] OR "betamethasone"[MeSH Terms] OR "steroids"[MeSH Terms] OR "Glucocorticoids"[MeSH Terms] OR "Adrenal Cortex Hormones"[MeSH Terms] OR

"hydrocortisone"[Text Word] OR "betamethason"[Text Word] OR
"dexamethason"[Text Word] OR "steroid"[Text Word] OR "corticoster"[Text Word] OR
"corticoid"[Text Word] OR "glucocortic"[Text Word] OR "adrenal cortex
hormone"[Text Word]) AND "English"[Language]

S2. Studies of glucocorticoids that reported a brain injury as a clinical characteristic.

We identified 50 studies that reported a brain injury outcome, most commonly IVH, as a characteristic of the study population after treatment with corticosteroid, but did not directly assess the effect of the steroid on brain injury. These studies are listed in the **Table**. (Sinkin et al., 2000) is a representative example of this category. Sinkin and colleagues conducted a multi-center, double blind phase 2 randomized controlled trial of a two dose course of dexamethasone early in neonatal life to assess the clinical efficacy and safety of the medication. The study population included infants under 30 weeks gestation with respiratory distress syndrome who required mechanical ventilation at 12-18 hours of life after surfactant. The dosing regimen was 0.5 mg dexamethasone administered via IV at 12-18 hours of life and 12 hours later. Later dexamethasone use was permitted per clinician discretion. The relevant brain outcome was presence and severity of IVH. 384 infants were enrolled and 189 received dexamethasone. There was no difference between the groups in incidence or severity of intraventricular hemorrhage. Of note, LeFlore (LeFlore JL et al., 2002) reported on an investigation of infants who received either no treatment, antenatal dexamethasone, postnatal dexamethasone only, or both antenatal and postnatal steroids. However, the aim of the

study and the reported results were on the effect of the antenatal exposure on cranial ultrasound at discharge. They report that the likelihood of abnormal ultrasound at discharge was greater in the postnatal dexamethasone groups compared with the no-postnatal dexamethasone groups. They do not report on the relationship between postnatal dexamethasone and specific cranial ultrasound findings as they do for antenatal dexamethasone at discharge.

S3. Glucocorticoids as risk factors

12 studies examined perinatal clinical risk factors and their effect on brain development (Batton et al., 2012; Cuzzilla R et al., 2018; Heo et al., 2018; Kelly CE et al., 2014; Kidokoro H et al., 2014; Matthews LG et al., 2018; Neubauer et al., 2017; Parikh NA et al., 2021; Thompson DK et al., 2008; Thompson et al., 2012; Vesoulis ZA et al., 2018; Watterberg et al., 2004). For the most part, steroid type and administration details are not specified. Whether or not steroid administration functions as a proxy for some other factor, such as pulmonary health, was not able to be discerned.

Table. Studies reporting brain injury as an outcome

Steroid	Imaging	Author Year	Study Type	Number of Participants	Administration Details	Brain outcome	Result
Dexamethasone	US	(Doyle et al., 2006)	RCT	70	0.15 mg/kg/d for 3d 0.10 mg/kg/d for 3d 0.05 mg/kg/d for 2d 0.02 mg/kg/d for 2d Total of 0.89 mg/kg over 10 days, intravenously	-Intraparenchymal Hemorrhage -Cystic PVL	No association
	US	(Gaissmaier and Pohlandt, 1999)	RCT	17	0.25mg/kg, intravenously Children who at completion of the study period were still receiving epinephrine received DEX (0.25 mg/kg) as a rescue dose. Age at first dose: 2d (1-20)	-IVH (Grade III-IV)	No association
	US	(LeFlore JL et al., 2002)	Cohort Study	173	0.3 – 0.5 mg/kg tapered over 14- to 42 days Age at first dose: 30 ± 14 days (no antenatal glucocorticoids) 25 ± 10 days (plus antenatal glucocorticoids)	Abnormal cranial ultrasound at discharge	Higher likelihood in infants exposed to postnatal dexamethasone
	US	(Lim G et al., 2015)	Cohort Study	131	3.18 mg/kg, 14d course 1.10 mg/kg, 10d course 1.59 mg/kg, 7d course Age at first dose: 21d or later	Severe-grade IVH/cystic PVL	No association
	US	(Lin et al., 1999)	RCT	40	1 dose q12hr, intravenously 0.25 mg/kg/dose, days 1-7 0.12 mg/kg/dose, days 8-14 0.05 mg/kg/dose, days 15-21 0.02 mg/kg/dose, days 22-28 Mean age at first dose: 8.0 ± 4.6 hrs.	-IVH (>Grade II)	No association
	US	(Malloy et al., 2005)	RCT	16	Low dose: 0.08 mg/kg/d for 7d High dose: 0.5 mg/kg/d for 3d followed by 0.3mg/kg/d for 4d. The daily dose for each group was divided into 2 doses q12hr, intravenously	-Mild, moderate, and severe ventricular hypertrophy	No association

Steroid	Imaging	Author Year	Study Type	Number of Participants	Administration Details	Brain outcome	Result
	US	(McEvoy et al., 2004)	RCT	62	High dose: 0.5 mg/kg/d for 3d, 0.25 mg/kg/d for 3d, 0.1 mg/kg/d on day 7. Total dose: 2.35 mg/kg Low dose: 0.2 mg/kg/d for 3d, 0.1 mg/kg/d for 4d. Total dose: 1mg/kg, All daily doses given q12hr, intravenously.	-PVL	No association
	US	(C. Romagnoli et al., 2002)	RCT	50	0.5 mg/kg/d for 3d 0.25 mg/kg/d for 3d 0.125 mg/kg/d on the 7th day Intravenously Age at first dose: 4d	-Major cranial US abnormalities at 12 months of corrected age. -Periventricular Leukomalacia.	No association
	US	(Sanders et al., 1994)	RCT	40	0.5 mg/kg, 2 doses q12hrs, intravenously Age at first dose: 12-18hrs.	-IVH (Grade I)	No association
	US	(Subhedar et al., 1997)	RCT	84	0.5 mg/kg/dose, 6 doses. 0.25 mg/kg/dose, 6 doses. 6d total, intravenously.	-IVH	Infants with an existing IVH were included in this study. Progression was detected only in control infants.
	US	(Sinkin et al., 2000)	RCT	384	0.5 mg/kg with the first dose administered between 12and 18hrs of age and the second dose 12hrs later, intravenously.	-IVH	No association
	US	(Stark et al., 2001)	RCT	220	0.15 mg/kg/d for 3d 0.10 mg/kg for 3d 0.05 mg/kg for 2d 0.02 mg/kg for 2d Intravenously or orally Age at first dose: 14.2 ± 5.8hrs	-IVH (Any grade) -Periventricular Leukomalacia	No association
	US	(Suske et al., 1996)	RCT	26	0.5 mg/kg, divided into 2 doses for 5d, intravenously Surfactant: 100mg/kg Age at first dose: <2hrs	-ICH (Grade I-II)	No association

Steroid	Imaging	Author Year	Study Type	Number of Participants	Administration Details	Brain outcome	Result
	US	(Tsukahara et al., 1999)	RCT	26	0.125 mg/kg, 6 doses q12hrs, intravenously Age at first dose: evening of day 4.	-Intracranial hemorrhage -Periventricular Leukomalacia	No association
	US	(Yaseen et al., 1999)	RCT	29	0.5mg/d for 2d 0.3 mg/kg/d for 2d 0.2 mg/kg/d on the 5th day of treatment, Intravenously Age at first dose 2.8 ± 1.01 hrs.	-IVH	No association
	US	(Yeh et al., 1990)	RCT	57	1 dose q12hrs, intravenously 0.5 mg/kg/dose, days 1-3 0.25 mg/kg/dose, days 4-6 0.12 mg/kg/dose, days 7-9 0.05 mg/kg/dose, days 10-12 Age at first dose: 8.5 ± 3.1 hrs.	-IVH	No association
	US	(Yeh et al., 1997)	RCT	262	1 dose q12hrs, intravenously 0.25 mg/kg/dose, days 1-7 0.12 mg/kg/dose, days 8-14 0.05 mg/kg/dose, days 15-21 0.02 mg/kg/dose, days 22-28 Age at first dose: 7.4 ± 5.2 hrs.	-IVH (Grade <II)	No association
	US	(Yeh et al., 1998)	RCT	133	0.25 mg/kg/dose bid, days 1-7 0.12 mg/kg/dose bid, days 8-14 0.05 mg/kg/dose bid, days 15-21 0.02 mg/kg/dose bid, days 22-28 Intravenously. Age at first dose: within 12hrs after birth	-IVH (Grade >II)	No association
	US	(Anttila E et al., 2005)	RCT	109	0.25 mg/kg, 4 doses, 2d q12hrs. Age at first dose: 6hrs.	-ICH (Grade III-IV) -PVL	No association
	US	(Brozanski et al., 1995)	RCT	78	0.25 mg/kg/dose twice daily for 3d, Intravenously, if IV not possible IM Age at first dose: 7d postnatal age.	-IVH (Grade <II)	Decreased incidence of worsening IVH
	US	(Durand et al., 1995)	RCT	43	0.5mg/kg/d, 2 divided doses for the first 3d	-IVH	No association

Steroid	Imaging	Author Year	Study Type	Number of Participants	Administration Details	Brain outcome	Result
					0.25 mg/kg/d for the next 3d 0.1 mg/kg/d on the 7th day of treatment, Intravenously		
	US	(Garland et al., 1999)	RCT	241	Age at first dose: 7-14d Total dose: 1.35 mg/kg over 3d (n=41) 1.175 mg/kg over 3d (n=77) 3-day tapering course q12hrs.	-ICH (Any grade) -PVL	No association
	US	(Kopelman AE et al., 1999)	RCT	70	Age at first dose: starting at 24 to 48hrs of life. 0.2mg/kg, 1 dose, intravenously Age at first dose: within 2hrs of delivery.	-IVH (Grade III-IV)	Study was terminated early because they were underpowered to detect differences in IVH. DEX group showed trends toward grade III-IV IVH and death.
	US	(Mieskonen et al., 2003)	RCT	16	0.5 mg/kg/d, divided into 2 doses Age at first dose: 28d.	-IVH	No association.

Steroid	Imaging	Author Year	Study Type	Number of Participants	Administration Details	Brain outcome	Result
	US	(Odd et al., 2004)	RCT	33	<p>Individual course: 0.5mg/kg/d for 3d, 0.3mg/kg/d for 3d, 0.1mg/kg/d for 3d, then 0.1mg/kg every 72hr until the infant was extubated and required a FiO₂ < 0.25 for three doses 9d). If there was clinical deterioration, the dose reverted to 0.3mg/kg/d for 3 days, then was weaned again using the same protocol. Total dose of 3.8 (2.0-5.7) mg/kg.</p> <p>42d course: 0.5mg/kg/d for 3d, 0.3mg/kg/d for 3d, then a dose decreasing by 10% every 3d to 0.1mg/kg/d over a further 30d, then 0.1mg/kg on alternate days for one further week. Total dose of 6.5 (3.8-7.3) mg/kg.</p>	-IVH (Grade III-IV)	No association
	US	(Rastogi et al., 1996)	RCT	70	<p>0.5mg/kg/d for 12d, intravenously</p> <p>Age at first dose: 7.2 ± 3hrs postnatal age.</p>	-IVH (Any grade)	No association
	US	(Romagnoli C et al., 1999)	RCT	50	<p>0.5 mg/kg/d for 3d 0.25 mg/kg/d for 3d 0.125 mg/kg/d on the 7th day of treatment, Intravenously</p> <p>Age at first dose: 4d.</p>	-ICH (Grade >II)	No association
	US	(C Romagnoli et al., 2002)	RCT	30	<p>0.5 mg/kg/d for 6d 0.25 mg/kg/d for 6d 0.125 mg/kg/d for 2d Total cumulative dose of 4.75 mg/kg, intravenously</p> <p>Age at first dose: 10d.</p>	-Major cranial US abnormalities at 12 months of corrected age. -Cystic PVL	No association
	US	(Shinwell et al., 1996)	RCT	248	<p>0.25 mg/kg, 6 doses q12hrs, intravenously</p> <p>Age at first dose: 1d.</p>	-IVH (Grade >II) -IVH (Grade <II) -PVL	No association
	US	(Shinwell et al., 1999)	RCT	159	<p>0.25 mg/kg, 6 doses q12hrs, intravenously</p>	-IVH (Grade I-IV)	No association.

Steroid	Imaging	Author Year	Study Type	Number of Participants	Administration Details	Brain outcome	Result
					Age at first dose: <12hrs.	-PVL	
	US	(Smets and Schwagten, 2000)	Case Control Study	48	0.125 mg/kg for 3d.	-Germinolysis	No association
	US	(Soll, 1999)	RCT	542	0.5 mg/kg/d for 3d 0.25mg/kg/d for 3d 0.10 mg/kg/d for 3d 0.05 mg/kg/d for 3d Intravenously	-IVH (Any grade) -PVL	No association
	US	(Tapia et al., 1998)	RCT	109	Age at first dose: 12hrs. 0.5mg/kg/d, days 1-3 0.25 mg/kg/d, days 4-6 0.12 mg/kg/d, days 7-9 0.06 mg/kg/d, days 10-12 Intravenously	-IVH	No association
	US	(Yates et al., 2019)	RCT	22	50 µg/kg, once daily on days 1-10 after randomization (i.e., 10 doses), then given on alternate days (i.e., on days 12, 14 and 16), making a total of 13 doses. Intravenously, nasogastric tube or orally. Total cumulative dose of 0.65 mg/kg.	-IVH (Any grade) -Hydrocephalus -PVL -Other white-matter injury	Determined it to not be feasible to conduct this trial due to low levels or recruitment.
Hydrocortisone	US	(Biswas et al., 2003)	RCT	253	1 mg/kg/d for days 1-4, then halved on day 5. Same dose days 5-7, intravenously	-IVH (Grade III-IV) -PVL	No association
	US	(Bonsante et al., 2007)	RCT	50	Age at first dose: 5hrs. 0.5 mg/kg, q12hr for 9d 0.5 mg/kg/d for 3d Intravenously	-IVH (Grade III) -PVL	No association
	US	(Bourchier and Weston, 1997)	RCT	40	Age at first dose: <48hrs of life. 2.5 mg/kg, 2 doses, 4hrs apart. Subsequent doses were q6hr for the remainder of the treatment period. The initial dose (2.5 mg/kg) was continued for 48hrs, followed by 1.25 mg/kg for 48hrs, then 0.625 mg/kg for a further 48hrs before stopping treatment, intravenously	-IVH (grades II-IV)	No association
					Age at first dose: 11.4hrs.		

Steroid	Imaging	Author Year	Study Type	Number of Participants	Administration Details	Brain outcome	Result
Hydrocortisone	US	(Efird et al., 2005)	RCT	34	1mg/kg BID for 2d 0.3 mg/kg BID for 3d Intravenously	-IVH (Grade >II) -PVL	No association
	US	(Ng et al., 2006)	RCT	48	1 mg/kg/dose, q8hr for 5d, intravenously	-IVH (Grade >III) -PVL	No association
	MRI/US	(Parikh et al., 2015)	RCT	57	q12h, 3mg/kg/d for 4 days, 2mg/kg/d for 2d, 1mg/kg/d for 1d. Total cumulative dose of 17 mg/kg, intravenously	-White matter injury near 36 weeks age (cystic periventricular leukomalacia, porencephalic cyst, parenchymal hemorrhage, and/or ventriculomegaly (with or without intraventricular hemorrhage)	No association
	US	(Verma RP et al., 2017)	Cohort Study	143	2-4 mg/kg/d, intravenously	-Ventriculomegaly (VM) -IVH	HC group had higher risk for IVH which declined in the multivariate analysis. A trend towards lower risk of VM was noted in HC group, which became significant after controlling for body weight.
	US	(Watterberg et al., 2007)	RCT	252	1 mg/kg/d (8 –10mg/m2/d) divided twice a day for 12d. Then 0.5 mg/kg/d for 3d	-IVH (Grade II-IV) -PVL	No association
	MRI	(Takayanagi et al., 2015)	Cohort Study	58	Intravenously: 9.0 ± 7.2 (1.0- 28.2) mg/kg Orally: 68.1 ± 34.1 (0-161.5) mg/kg. Mean duration of 57.1 ± 27.8 (0-154) d.	MRI abnormality (focal high intensity of white matter or irregular ventricular wall with mild dilation)	No difference in hydrocortisone dose between patients with and without MRI abnormality

Steroid	Imaging	Author Year	Study Type	Number of Participants	Administration Details	Brain outcome	Result
	MRI, US	(Baud et al., 2016)	RCT	521	1mg/kg/d, 2 doses for 7d 0.5mg/kg/d, 1 dose for 3d Intravenously	-IVH (Grade III-IV) -Cystic PVL	No association
	US	(Onland et al., 2019)	RCT	372	5 mg/kg/d, 4 doses/d for 7d 3.75 mg/kg/d, 3 doses/d for 5d, subsequently lowering the frequency by 1 dose every 5 days. Cumulative dose of 72.5 mg/kg. Age at first dose: between 7- 14d 3.75 mg/kg/d, 3 doses/d for 5d, subsequently lowering the frequency by 1 dose every 5 days. Cumulative dose: 72.5 mg/kg.	-IVH (Grade >II) -PVL	No association
	US	(Peltoniemi et al., 2005)	RCT	51	2.0 mg/kg, divided into 3 doses q8hrs for 2d 1.5 mg/kg, divided into 3 doses q8hrs for 2d 0.75 mg/kg, divided into 2 doses q12hrs for 6d Intravenously Age at first dose: before the age of 36hrs.	-IVH (Any grade) -Cystic PVL	No association
Betamethasone	US	(Smolkin et al., 2014)	Cohort Study	35	0.1 mg/kg/dose, twice daily for 3d 0.05 mg/kg/dose twice daily for 2d 0.05 mg/kg/dose once daily for 2d Orally (PO) Mean age at first dose: 31.0 ± 13.6 d.	-PVL	No association
Budesonide	US	(Bassler et al., 2015)	RCT	856	Two inhaled puffs of 200 µg each q12hr in the first 14d of life and one puff q12hr from day 15 until the last dose of the study drug had been administered. Age at first dose: 12hrs after random assignment.	-Brain injury	No association

Steroid	Imaging	Author Year	Study Type	Number of Participants	Administration Details	Brain outcome	Result
Dexamethasone and Budesonide	US	(Kovács et al., 1998)	RCT	60	DEX (IV): 0.25 mg/kg, q12hr for 3d BUD (INH): 500mg, twice daily for 18d Age at first dose: 7d.	-IVH (Any grade)	No association
	US	(Halliday et al., 2001)	RCT	570	DEX (IV): 0.50mg/kg/d, 2 divided doses for 3d 0.25mg/kg/d, 2 divided doses for 3d 0.10mg/kg/d, 2 divided doses for 3d 0.05mg/kg/d, 2 divided doses for 3d BUD (INH): A 500- to 1000-g infant was given 400mg (2 puffs) twice daily and a 1000- to 1500-g infant 600mg (3 puffs) twice daily. Age at first dose: Early cohort: <72 hours Delayed cohort: >15 days	- major cerebral abnormality -IVH	No association

- Anttila E, Peltoniemi O, Haumont D, Herting E, ter Horst H, Heinonen K, Kero P, Nykänen P, Oetomo SB, Hallman M, 2005. Early neonatal dexamethasone treatment for prevention of bronchopulmonary dysplasia. Randomised trial and meta-analysis evaluating the duration of dexamethasone therapy. *Eur J Pediatr* 164, 472–81. <https://doi.org/10.1007/s00431-005-1645-8>
- Bassler, D., Plavka, R., Shinwell, E.S., Hallman, M., Jarreau, P.-H., Carnielli, V., Van den Anker, J.N., Meisner, C., Engel, C., Schwab, M., Halliday, H.L., Poets, C.F., 2015. Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia. *N Engl J Med* 373, 1497–1506. <https://doi.org/10.1056/NEJMoa1501917>
- Batton, B.J., Li, L., Newman, N.S., Das, A., Watterberg, K.L., Yoder, B.A., 2012. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Feasibility study of early blood pressure management in extremely preterm infants. *Journal of Pediatrics* 161, 65–9. <https://doi.org/10.1016/j.jpeds.2012.01.014>
- Baud, O., Maury, L., Lebail, F., Ramful, D., El Moussawi, F., Nicaise, C., Zupan-Simunek, V., Coursol, A., Beuchée, A., Bolot, P., Andrini, P., Mohamed, D., Alberti, C., PREMIOLOC trial study group, 2016. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMIOLOC): a double-blind, placebo-controlled, multicentre, randomised trial. *Lancet* 387, 1827–1836. [https://doi.org/10.1016/S0140-6736\(16\)00202-6](https://doi.org/10.1016/S0140-6736(16)00202-6)
- Biswas, S., Buffery, J., Enoch, H., Bland, M., Markiewicz, M., Walters, D., 2003. Pulmonary effects of triiodothyronine (T3) and hydrocortisone (HC) supplementation in preterm infants less than 30 weeks' gestation: results of the THORN trial - thyroid hormone replacement in neonates. *Pediatric Research* 53, 48–56. <https://doi.org/10.1203/00006450-200301000-00011>
- Bonsante, F., Latorre, G., Iacobelli, S., Forziati, V., Laforgia, N., Esposito, L., 2007. Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. *Neonatology* 91, 217–21. <https://doi.org/10.1159/000098168>
- Bourchier, D., Weston, P.J., 1997. Randomised trial of dopamine compared with hydrocortisone for the treatment of hypotensive very low birthweight infants. *Arch Dis Child Fetal Neonatal Ed* 76, F174-178. <https://doi.org/10.1136/fn.76.3.f174>
- Brozanski, B., Jones, J., Gilmour, C., Balsan, M., Vazquez, R., Israel, B., Newman, B., Mimouni, F., Guthrie, R., 1995. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. *Journal of pediatrics* 126, 769-776. [https://doi.org/10.1016/s0022-3476\(95\)70410-8](https://doi.org/10.1016/s0022-3476(95)70410-8)
- Cuzzilla R, Spittle AJ, Lee KJ, Rogerson S, Cowan FM, Doyle LW, Cheong JLY, 2018. Postnatal Brain Growth Assessed by Sequential Cranial Ultrasonography in Infants Born <30 Weeks' Gestational Age. *AJNR Am J Neuroradiol* 39, 1170–1176. <https://doi.org/10.3174/ajnr.A5679>
- Doyle, L.W., Davis, P.G., Morley, C.J., McPhee, A., Carlin, J.B., 2006. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. *Pediatrics* 117, 75–83. <https://doi.org/10.1542/peds.2004-2843>

- Durand, M., Sardesai, S., McEvoy, C., 1995. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. *Pediatrics* 95, 584-590.
- Efird, M.M., Heerens, A.T., Gordon, P.V., Bose, C.L., Young, D.A., 2005. A randomized-controlled trial of prophylactic hydrocortisone supplementation for the prevention of hypotension in extremely low birth weight infants. *Journal of Perinatology* 25, 119–24. <https://doi.org/10.1038/sj.jp.7211193>
- Gaissmaier, R.E., Pohlandt, F., 1999. Single-dose dexamethasone treatment of hypotension in preterm infants. *Journal of Pediatrics* 134, 701–5. [https://doi.org/10.1016/s0022-3476\(99\)70284-2](https://doi.org/10.1016/s0022-3476(99)70284-2)
- Garland, J.S., Alex, C.P., Pauly, T.H., Whitehead, V.L., Brand, J., Winston, J.F., 1999. A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. *Pediatrics* 104, 91–9. <https://doi.org/10.1542/peds.104.1.91>
- Halliday, H.L., Patterson, C.C., Halahakoon, C.W., 2001. A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. *Pediatrics* 107, 232–40.
- Heo, J.S., Kim, E.-K., Choi, Y.H., Shin, S.H., Sohn, J.A., Cheon, J.-E., Kim, H.-S., 2018. Timing of sepsis is an important risk factor for white matter abnormality in extremely premature infants with sepsis. *Pediatr Neonatol* 59, 77–84. <https://doi.org/10.1016/j.pedneo.2017.07.008>
- Kelly CE, Cheong JL, Molloy C, Anderson PJ, Lee KJ, Burnett AC, Connelly A, Doyle LW, Thompson DK, 2014. Neural correlates of impaired vision in adolescents born extremely preterm and/or extremely low birthweight. *PLoS One* 9, e93188. <https://doi.org/10.1371/journal.pone.0093188>
- Kidokoro H, Anderson PJ, Doyle LW, Woodward LJ, Neil JJ, Inder TE, 2014. Brain injury and altered brain growth in preterm infants: predictors and prognosis. *Pediatrics* 134, e444-53. <https://doi.org/10.1542/peds.2013-2336>
- Kopelman AE, Moise AA, Holbert D, Hegemier SE, 1999. A single very early dexamethasone dose improves respiratory and cardiovascular adaptation in preterm infants. *J Pediatr* 135, 345–50. [https://doi.org/10.1016/s0022-3476\(99\)70132-0](https://doi.org/10.1016/s0022-3476(99)70132-0)
- Kovács, L., Davis, G., Faucher, D., Papageorgiou, A., 1998. Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. *Acta paediatrica* 87, 792-798. <https://doi.org/10.1080/080352598750013905>
- LeFlore JL, Salhab WA, Broyles RS, Engle WD, 2002. Association of antenatal and postnatal dexamethasone exposure with outcomes in extremely low birth weight neonates. *Pediatrics* 110, 275–9. <https://doi.org/10.1542/peds.110.2.275>
- Lim G, Lee BS, Choi YS, Park HW, Chung ML, Choi HJ, Kim EA, Kim KS, 2015. Delayed Dexamethasone Therapy and Neurodevelopmental Outcomes in Preterm Infants with Bronchopulmonary Dysplasia. *Pediatr Neonatol* 56, 261–7. <https://doi.org/10.1016/j.pedneo.2014.11.006>

- Lin, Y.J., Yeh, T.F., Hsieh, W.S., Chi, Y.C., Lin, H.C., Lin, C.H., 1999. Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy. *Pediatric Pulmonology* 27, 21–6. [https://doi.org/10.1002/\(sici\)1099-0496\(199901\)27:1](https://doi.org/10.1002/(sici)1099-0496(199901)27:1)
- Malloy, C.A., Hilal, K., Weiss, M.G., Rizvi, Z., Muraskas, J.K., 2005. A prospective, randomized, double-masked trial comparing low dose to conventional dose dexamethasone in neonatal chronic lung disease. *Internet Journal of Pediatrics and Neonatology* 5.
- Matthews LG, Inder TE, Pascoe L, Kapur K, Lee KJ, Monson BB, Doyle LW, Thompson DK, Anderson PJ, 2018. Longitudinal Preterm Cerebellar Volume: Perinatal and Neurodevelopmental Outcome Associations. *Cerebellum* 17, 610–627. <https://doi.org/10.1007/s12311-018-0946-1>
- McEvoy, C., Bowling, S., Williamson, K., McGaw, P., Durand, M., 2004. Randomized, double-blinded trial of low- dose dexamethasone: II. Functional residual capacity and pulmonary outcome in very low birth weight infants at risk for bronchopulmonary dysplasia. *Pediatric Pulmonology* 38, 55–63.
- Mieskonen, S., Eronen, M., Malmberg, L., Turpeinen, M., Kari, M., Hallman, M., 2003. Controlled trial of dexamethasone in neonatal chronic lung disease: an 8-year follow-up of cardiopulmonary function and growth. *Acta paediatrica* 92, 896-904.
- Neubauer, V., Djurdjevic, T., Griesmaier, E., Biermayr, M., Gizewski, E.R., Kiechl-Kohlendorfer, U., 2017. Routine Magnetic Resonance Imaging at Term-Equivalent Age Detects Brain Injury in 25% of a Contemporary Cohort of Very Preterm Infants. *PLoS ONE* 12, e0169442. <https://doi.org/10.1371/journal.pone.0169442>
- Ng, P.C., Lee, C.H., Bnur, F.L., Chan, I.H., Lee, A.W., Wong, E., 2006. A double-blind, randomized, controlled study of a “stress dose” of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. *Pediatrics* 117, 367–75. <https://doi.org/10.1542/peds.2005-0869>
- Odd, D.E., Armstrong, D.L., Teele, R.L., Kuschel, C.A., Harding, J.E., 2004. A randomized trial of two dexamethasone regimens to reduce side-effects in infants treated for chronic lung disease of prematurity. *Journal of Paediatrics and Child Health* 40, 282–9. <https://doi.org/10.1111/j.1440-1754.2004.00364.x>
- Onland, W., Cools, F., Kroon, A., Rademaker, K., Merkus, M.P., Dijk, P.H., 2019. Effect of hydrocortisone therapy initiated 7 to 14 days after birth on mortality or bronchopulmonary dysplasia among very preterm infants receiving mechanical ventilation: a randomized clinical trial. *JAMA* 321, 354–63. <https://doi.org/10.1001/jama.2018.21443>
- Parikh, N., Kennedy, K., Lasky, R., Tyson, J., 2015. Neurodevelopmental Outcomes of Extremely Preterm Infants Randomized to Stress Dose Hydrocortisone. *PLoS one* 10, e0137051. <https://doi.org/10.1371/journal.pone.0137051>
- Parikh NA, Sharma P, He L, Li H, Altaye M, Priyanka Illapani VS, 2021. Perinatal Risk and Protective Factors in the Development of Diffuse White Matter Abnormality on Term-Equivalent Age Magnetic Resonance Imaging in Infants Born Very Preterm. *J Pediatr* 233, 58-65.e3. <https://doi.org/10.1016/j.jpeds.2020.11.058>
- Peltoniemi, O., Kari, M.A., Heinonen, K., Saarela, T., Nikolajev, K., Andersson, S., 2005. Pretreatment cortisol values may predict responses to hydrocortisone administration

- for the prevention of bronchopulmonary dysplasia in high-risk infants. *Journal of Pediatrics* 146, 632–7. <https://doi.org/10.1016/j.jpeds.2004.12.040>
- Rastogi, A., Akintorin, S.M., Bez, M.L., Morales, P., Pildes, R.S., 1996. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. *Pediatrics* 98, 204–10.
- Romagnoli, C., Zecca, E., Luciano, R., Torrioli, G., Tortorolo, G., 2002. Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. *Pediatrics* 109. <https://doi.org/10.1542/peds.109.6.e85>
- Romagnoli, C., Zecca, E., Luciano, R., Torrioli, G., Tortorolo, G., 2002. A three year follow-up of preterm infants after moderately early treatment with dexamethasone. *Archives of disease of childhood fetal and neonatal edition* 87, F55-8.
- Romagnoli C, Zecca E, Vento G, De Carolis MP, Papacci P, Tortorolo G, 1999. Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants. *Intensive Care Med* 25, 717–21. <https://doi.org/10.1007/s001340050935>
- Sanders, R.J., Cox, C., Phelps, D.L., Sinkin, R.A., 1994. Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. *Pediatric Research* 36, 122–8. <https://doi.org/10.1203/00006450-199407001-00022>
- Shinwell, E., Karplus, M., Reich, D., 1999. Early dexamethasone therapy is associated with increased incidence of cerebral palsy 240-254.
- Shinwell, E.S., Karplus, M., Zmora, E., Reich, D., Rothschild, A., Blazer, S., 1996. Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. *Archives of Disease in Childhood. Fetal and Neonatal Edition* 74. <https://doi.org/10.1136/fn.74.1.f33>
- Sinkin, R.A., Dweck, H.S., Horgan, M.J., Gallaher, K.J., Cox, C., Maniscalco, W.M., 2000. Early dexamethasone - attempting to prevent chronic lung disease. *Pediatrics* 105, 542–8. <https://doi.org/10.1542/peds.105.3.542>
- Smets, K., Schwagten, B., 2000. Postnatal cystic germinolysis and neonatal chronic lung disease: evaluation of risk factors and neurodevelopmental outcome. *Acta Paediatr* 89, 1111–1114. <https://doi.org/10.1080/713794556>
- Smolkin, T., Ulanovsky, I., Jubran, H., Blazer, S., Makhoul, I.R., 2014. Experience with oral betamethasone in extremely low birthweight infants with bronchopulmonary dysplasia. *Archives of Disease in Childhood. Fetal and Neonatal Edition* 99. <https://doi.org/10.1136/archdischild-2014-306619>
- Soll, R.F., 1999. Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. *Pediatric Research* 45.
- Stark, A.R., Carlo, W.A., Tyson, J.E., Papile, L.A., Wright, L.L., Shankaran, S., 2001. National Institute of Child Health and Human Development Neonatal Research Network. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. *New England Journal of Medicine* 344, 95–101. <https://doi.org/10.1056/NEJM200101113440203>
- Subhedar, N.V., Ryan, S.W., Shaw, N.J., 1997. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. *Archives of Disease in Childhood. Fetal and Neonatal Edition* 77. <https://doi.org/10.1136/fn.77.3.f185>

- Suske, G., Oestreich, K., Varnholt, V., Lasch, P., Kachel, W., 1996. Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant-substituted preterm infants. *Acta Paediatrica* 85, 713–8. <https://doi.org/10.1111/j.1651-2227.1996.tb14132.x>
- Takayanagi, T., Matsuo, K., Egashira, T., Mizukami, T., 2015. Neonatal hydrocortisone therapy does not have a serious suppressive effect on the later function of the hypothalamus-pituitary-adrenal axis. *Acta Paediatr.* 104, e195-199. <https://doi.org/10.1111/apa.12926>
- Tapia, J.L., Ramirez, R., Cifuentes, J., Fabres, J., Hubner, M.E., Bancalari, A., 1998. The effect of early dexamethasone administration on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome. *Journal of Pediatrics* 132, 48–52. [https://doi.org/10.1016/s0022-3476\(98\)70483-4](https://doi.org/10.1016/s0022-3476(98)70483-4)
- Thompson, D.K., Inder, T.E., Faggian, N., Warfield, S.K., Anderson, P.J., Doyle, L.W., Egan, G.F., 2012. Corpus callosum alterations in very preterm infants: perinatal correlates and 2 year neurodevelopmental outcomes. *Neuroimage* 59, 3571–81. <https://doi.org/10.1016/j.neuroimage.2011.11.057>
- Thompson DK, Wood SJ, Doyle LW, Warfield SK, Lodygensky GA, Anderson PJ, Egan GF, Inder TE, 2008. Neonate hippocampal volumes: prematurity, perinatal predictors, and 2-year outcome. *Ann Neurol* 63, 642–51. <https://doi.org/10.1002/ana.21367>
- Tsukahara, H., Watanabe, Y., Yasutomi, M., Kobata, R., Tamura, S., Kimura, K., 1999. Early (4-7 days of age) dexamethasone therapy for prevention of chronic lung disease in preterm infants. *Biology of the Neonate* 76, 283–90. <https://doi.org/10.1159/000014170>
- Verma RP, Dasnadi S, Zhao Y, Chen HH, 2017. A comparative analysis of ante- and postnatal clinical characteristics of extremely premature neonates suffering from refractory and non-refractory hypotension: Is early clinical differentiation possible? *Early Hum Dev* 113, 49–54. <https://doi.org/10.1016/j.earlhumdev.2017.07.010>
- Vesoulis ZA, Herco M, Mathur AM, 2018. Divergent risk factors for cerebellar and intraventricular hemorrhage. *J Perinatol* 38, 278–284. <https://doi.org/10.1038/s41372-017-0010-x>
- Watterberg, K.L., Gerdes, J.S., Cole, C.H., Aucott, S.W., Thilo, E.H., Mammel, M.C., 2004. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. *Pediatrics* 114, 1649–57. <https://doi.org/10.1542/peds.2004-1159>
- Watterberg, K.L., Shaffer, M.L., Mishefske, M.J., Leach, C.L., Mammel, M.C., Couser, R.J., Abbasi, S., Cole, C.H., Aucott, S.W., Thilo, E.H., Rozycki, H.J., Lacy, C.B., 2007. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. *Pediatrics* 120, 40–48. <https://doi.org/10.1542/peds.2006-3158>
- Yaseen, H., Okash, I., Hanif, M., al-Umran, K., al-Faraidy, A., 1999. Early dexamethasone treatment in preterm infants treated with surfactant: a double blind controlled trial. *Journal of Tropical Pediatrics* 45, 304–6. <https://doi.org/10.1093/tropej/45.5.304>
- Yates, H., Chiochia, V., Linsell, L., Orsi, N., Juszczak, E., Johnson, K., 2019. Very low-dose dexamethasone to facilitate extubation of preterm babies at risk of bronchopulmonary dysplasia: the MINIDEX feasibility RCT. *Efficacy and Mechanism Evaluation* 6. <https://doi.org/10.3310/eme06080>

- Yeh, T.F., Lin, Y.J., Hsieh, W.S., Lin, H.C., Lin, C.H., Chen, J.Y., 1997. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. *Pediatrics* 100. <https://doi.org/10.1542/peds.100.4.e3>
- Yeh, T.F., Lin, Y.J., Huang, C.C., Chen, Y.J., Lin, C.H., Lin, H.C., 1998. Early dexamethasone therapy in preterm infants: a follow-up study. *Pediatrics* 101. <https://doi.org/10.1542/peds.101.5.e7>
- Yeh, T.F., Torre, J.A., Rastogi, A., Anyebuno, M.A., Pildes, R.S., 1990. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. *Journal of Pediatrics* 117, 273–82. [https://doi.org/10.1016/s0022-3476\(05\)80547-5](https://doi.org/10.1016/s0022-3476(05)80547-5)